**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 66965

**Manuscript Type:** REVIEW

**Transfusion-transmitted hepatitis E: What we know so far?**

Cheung CKM *et al*. Transfusion-transmitted hepatitis E

Carmen Ka Man Cheung, Sunny Hei Wong, Alvin Wing Hin Law, Man Fai Law

**Carmen Ka Man Cheung, Man Fai Law,** Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong 852, China

**Sunny Hei Wong,** Institute of Digestive Disease and Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong 852, China

**Sunny Hei Wong,** Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore

**Alvin Wing Hin Law,** West Island School, Hong Kong 852, China

**Author contributions:** Cheung CKM contributed to acquisition, analysis and interpretation of data/references; drafted and approved the manuscript; Wong SH contributed to analysis, interpretation of data/references; revised critically and approved the manuscript; Law AWH contributed to analysis of data/references and approved the manuscript; Law MF contributed to acquisition, analysis and interpretation of data/references, and drafted and approved the manuscript.

**Corresponding author: Man Fai Law, MRCP, Doctor,** Medicine and Therapeutics, Prince of Wales Hospital, 30-32 Ngai Shing Street, Shatin, Hong Kong 852, China. mflaw99@yahoo.com.hk

**Received:** April 10, 2021

**Revised:** July 16, 2021

**Accepted: December 22, 2021**

**Published online:**

**Abstract**

Hepatitis E virus (HEV) is a major cause of viral hepatitis globally. There is growing concern about transfusion-transmitted HEV (TT-HEV) as an emerging global health problem. HEV can potentially result in chronic infection in immunocompromised patients, leading to a higher risk of liver cirrhosis and even death. Between 0.0013% and 0.281% of asymptomatic blood donors around the world have HEV viremia, and 0.27% to 60.5% have anti-HEV immunoglobulin G. HEV is infectious even at very low blood concentrations of the virus. Immunosuppressed patients who develop persistent hepatitis E infection should have their immunosuppressant regimen reduced; ribavirin may be considered as treatment. Pegylated interferon can be considered in those who are refractory or intolerant to ribavirin. Sofosbuvir, a nucleotide analog, showed modest antiviral activity in some clinical studies but sustained viral response was not achieved. Therefore, rescue treatment remains an unmet need. The need for HEV screening of all blood donations remains controversial. Universal screening has been adopted in some countries after consideration of risk and resource availability.Various pathogen reduction methods have also been proposed to reduce the risk of TT-HEV. Future studies are needed to define the incidence of transmission through transfusion, their clinical features, outcomes and prognosis.

**Key Words:** Hepatitis E virus; Acute and chronic hepatitis; Immunosuppression; Blood transfusion; Transplantation

Cheung CKM, Wong SH, Law AWH, Law MF. Transfusion-transmitted hepatitis E: What we know so far? *World J Gastroenterol* 2021; In press

**Core Tip:** Transfusion-transmitted hepatitis E virus (HEV) is an emerging global health concern. In immunocompromised patients, chronic HEV infection increases the risk of liver cirrhosis. The prevalence of viremia and anti-HEV immunoglobulin G in asymptomatic blood donors varies widely between countries but even low concentrations of HEV in blood components are infectious, and in most countries blood donations are not routinely screened for HEV. Treatment of persistent infection includes modification of the immunosuppressant regimen followed by ribavirin. The need for screening of HEV in all blood donations remains controversial. Strategies to reduce de novo HEV infection should also be emphasized.

**INTRODUCTION**

Hepatitis E virus (HEV) was first discovered as an epidemic of non-A, non-B hepatitis in the 1980s[1], and has since become one of the major global causes of viral hepatitis. The World Health Organization estimated that HEV caused approximately 44000 deaths in 2015, and accounted for 3.3% of global deaths related to viral hepatitis[2]. A recent meta-analysis concluded that approximately 939 million of the global population have ever experienced HEV infection, and 15 to 110 million individuals have recent or ongoing infection[3]. The infection is generally self-limiting; however, it poses a threat to some vulnerable patients resulting in a significant burden of in-patient admissions, chronic infection, organ failure, and death[4]. The mortality rate can be greater than 20% in patients with chronic liver disease, cirrhosis, or pregnancy[4,5]. With a high HEV serological prevalence among the global population, the safety of blood products has become a public health concern. Herein, we review existing evidence on transfusion-transmitted HEV (TT-HEV), and the implications for screening of blood donations.

**VIROLOGY**

HEV is a positive-sense, single-stranded RNA icosahedral virus belonging to the genus *Orthohepevirus* within the Hepeviridae family[6]. *Orthohepevirus A* has eight distinct genotypes, of which HEV-1, -2, -3 and -4 infect humans[7]. HEV genotype C1, belonging to the species *Orthohepevirus C*, circulates in rats and can cause cross-species infection and sporadic zoonotic transmission to humans[8].

HEV exists in urine or feces as non-enveloped virions encased by a capsid. It circulates in blood in a membrane-associated, quasi-enveloped form (eHEV) which is considered to be less contagious[9]. The entry mechanisms for HEV are not well characterized, but once the genomic RNA is uncoated and delivered to the cytosol, the replication cycle is initiated[10]. The viral release that initiates subsequent infection requires multivesicular bodies through endosomal sorting complexes required for transport[11].

**EPIDEMIOLOGY**

The prevalence rates of HEV antibody are higher in developing countries than in developed countries[12]. The highest anti-HEV immunoglobulin G (IgG) seropositivity rate has been reported in Africa with a mean of 21.76%, followed by Asia (15.80%), Europe (9.31%), North America (8.05%), South America (7.28%), and Oceania (5.99%). In addition, the reported anti-HEV immunoglobulin M (IgM) seroprevalence rate was 3.09%, 1.86%, 0.79%, 0.22% and 2.43% in Africa, Asia, Europe, North America, and South America, respectively[3].

Among the four major genotypes that can infect humans, HEV-1 and -2 are mostly found in developing countriesincluding Asia, Africa, Latin America, and Mexico. Infection is mainly transmitted *via* fecally contaminated water, but occasionally also by person-to-person and vertical transmission[13]. Hepatitis E occurs as outbreaks as well as sporadic cases of acute hepatitis, with the preponderance of cases among adolescents and young adults. When stratified by age, the estimated incidence of HEV-1 and -2 infection is roughly between 0.5% and 1.0% for ages 0 to 15 years, with rates increasing to between 1.0% and 1.4% for ages 15 years to 20 years, then falling rapidly to a lower rate of 0.2% and below in individuals older than 30 years[14].

HEV-3 accounts for most of the autochthonous infection in developed countries while HEV-4 is mainly found in Asia and sporadically in Europe[15,16]. The reported seroprevalence of HEV-3 ranged from 0.6% to 52.5% in Europe, 6% in United States, 3 to 16% in United Kingdom and up to 52% in some regions of France[17]. HEV-3 and HEV-4 are zoonotic viruses which are frequently transmitted *via* food, close contact with animals, or transfusion of viremic blood units[18].

**CLINICAL FEATURES AND EXTRAHEPATIC MANIFESTATIONS**

The incubation period following exposure to HEV ranges from 2 to 6 wks. HEV infection commonly takes a clinically silent, asymptomatic course with around 5% to 30% of infected individuals developing acute hepatitis[19]. Symptoms of acute hepatitis include fever, malaise, anorexia, vomiting, followed by jaundice, tea-colored urine, and hepatomegaly[20]. It is then followed by a convalescent phase with gradual recovery within a few weeks in immunocompetent patients[21]. Acute liver failure is rare and occurs more frequently in middle-aged/elderly patients[22]. Fulminant hepatitis with fatal outcome is uncommon, but has been observed in pregnant women or in patients with pre-existing liver disease. The development of fulminant hepatitis appears to be related to host-specific factors rather than virus genotype, variants, or specific substitutions[23]. HEV superinfection may trigger liver decompensation in patients with chronic liver disease or cirrhosis, resulting in acute-on-chronic liver failure, which is associated with signiﬁcant short-term mortality[24,25]. Further research is needed to clarify the clinical features, course of illness, and prognosis of patients with decompensated cirrhosis who develop HEV infection.

HEV-3 and HEV-4 can persist in immunocompromised patients resulting in chronic infection, defined as viral replication lasting for more than 3 to 6 mo[26]. It has been well described in patients after solid organ or stem cell transplant, hematology patients receiving chemotherapy, or HIV-infected patients[27-32]. The prevalence of anti-HEV IgG was about 11.6% and viral RNA was 2% in solid organ transplant recipients[33]. In solid organ transplant recipients who were positive for HEV RNA, more than 60% developed chronic hepatitis[33].

The natural history of chronic hepatitis E infection is not well understood[34]. In liver transplant recipients infected by HEV, histological analyses of liver biopsy revealed atypical morphology that is distinct from those in immunocompetent patients during early phases of infection[35]. Proliferation of, and cytokine production by, CD4+ and CD8+ T-cells were impaired in patients with persistent HEV viremia[36]. Chronic hepatitis E leads to liver fibrosis and cirrhosis. Cases of HEV-related hepatocellular carcinoma have been reported[37].

Although HEV predominantly infects hepatocytes, it may also affect other organs and present as extrahepatic manifestations. The mechanisms by which HEV can induce extrahepatic manifestations are not fully understood, but hypotheses include direct cytopathic tissue damage by extrahepatic replication, or immunological processes induced by an overwhelming host immune response[38]. Details of extrahepatic manifestations are shown in Table 1[39-44].

**PREVALENCE IN BLOOD DONORS**

***Viremia***

The prevalence of HEV RNA in blood donors varies around the world. (Table 2)[45-78]. Most countries have a low prevalence of HEV viremia, ranging from 0.0013% to 0.086%. A relatively higher rate of viremia was reported in Germany (0.12%) and China (0.281%)[49,70]. A meta-analysis of 10 studies from China showed a pooled prevalence of HEV RNA of 0.1%[79]. The actual prevalence might have been underestimated as some studies included in the meta-analysis conducted RNA detection only in those donors who were positive for anti-HEV IgM or antigen[79].

The prevalence of HEV-3 and -4 is affected by dietary habits[80]. Consumption of raw pork tartare and undercooked pork liver may represent a relevant risk factor for HEV infection in Germany[49].Regular consumption of pork meat and shellfish were also reported in the viremic donors in China[70].

Since 70% of infections with HEV-3 and -4 are asymptomatic[81], it can be difficult to identify infected blood donors, as viremia occurs primarily during the pre-icteric phase[82]. Katiyar *et al*[72] described anti-HEV IgG positivity in 60.5% of the tested donors in India and yet none of them were positive for HEV RNA. In India, human HEV is caused exclusively by the HEV-1 genotype, which causes brief hepatitis and seldom results in chronic infection[83,84]. The difference in endemicity between HEV genotypes may affect the propensity to cause symptomatic disease and viral persistence, which in turn influences the likelihood of viremia among blood donors.

Other factors influencing the reported prevalence of HEV viremia are the sensitivity and plasma pool size of the various nucleic acid test screening platforms used[85]. For example, 33 of 90 donations with a viral load of 20-750 IU/mL were positive when tested individually but missed in the pooled screening in a study by Hogema *et al*[57]. Delage *et al*[66] revealed a low prevalence (*n* = 11/50765) and viral loads of HEV-RNA in Canadian blood donors based on individual nucleic acid amplification techniques (NAT). They postulated that if pooled NAT was used, only two positive donations with viral loads > 1000 IU/mL would have been detected.The true frequency of viremia in blood donors in studies using pooled NAT could be underestimated due to a dilution effect. Vollmer *et al*[86] found that screening using individual NAT yielded an approximately 50% higher detection frequency compared with NAT of a mini-pool of 96 samples; nevertheless, samples exclusively positive for individual NAT had a corresponding viral load of < 25 IU/mL. High-sensitivity individual NAT can yield false-positive results[55].Whether the identification of low-level HEV-positive donors translates into clinical significance and whether a single individual NAT is adequate remain undefined.

***Antibodies***

In addition to direct detection of HEV RNA, another important indirect assessment of HEV burden is the prevalence of anti-HEV IgM and IgG in blood donors (Table 3)[45,46,54-56,58,59,61,63,65,68,69,71,72,77,87-124]. HEV IgG prevalence increases with age which likely represents the cumulative effect of HEV exposure over a lifetime, especially as IgG antibodies can persist for decades[81]. The absence of detectable antibodies in donors was related to an increased risk of transfusion transmission of HEV[64]. However, the presence of anti-HEV IgG may not always be protective as multiple HEV reinfections could occur despite pre-existing antibodies[125]. Various HEV strains in serum are capable of replication in cell culture and generate infectious particles in the culture supernatant despite the coexistence of antibodies[126]. Anti-HEV IgM could be used to detect recent infection yet it failed to identify infected donors during the window period. For example, a meta-analysis of data from 28 countries found that only 26.6% of viremic blood units had positive anti-HEV antibodies[127]. In another study by Tedder *et*[128] *al*, a significant portion of viremic individuals (*n* = 57/79) were seronegative at the time of donation. Anti-HEV IgM sometimes exhibits unexpectedly long persistence for up to 3 years after a self-limiting acute hepatitis E episode[129]. Only a minority of anti-HEV IgM-positive donors have detectable RNA[58,93,103,109]. All these findings suggest that detection of anti-HEV IgG or IgM alone may not provide effective screening of HEV in blood donors.

Geographical variation, racial differences, and diverse study methodology and laboratory techniques all contribute to differences in HEV seroprevalence. More than one-third of donors had evidence of past HEV infection in Poland, India, Nepal and Burkina Faso[59,72,117,120]. Lucarelli *et al*[93] reported an unexpectedly high prevalence (48.9%) of anti-HEV IgG among 313 donors in central Italy. Eating raw dried pig liver sausage was the only independent risk factor for HEV IgG in their study, but the authors speculated that the uncontrolled expansion of the wild boar population had resulted in contamination of the soil and watercourses for people living in rural areas, and this may also have also contributed to the high prevalence of HEV[93].

Caution is needed when interpreting the HEV serology results because commercial kits for serological detection show marked variation in sensitivity and specificity. Despite the relatively high sensitivity of the IgM assay, the sensitivity of IgG detection kits is highly dependent on a patient’s immune status, being 80% to 90% in immunocompetent individuals, but falling dramatically to 15% to 45% in immunocompromised patients[130]. In a meta-analysis conducted in Europe, the pooled anti-HEV IgG seroprevalence rates determined by different commercial assays showed large variability with reported seroprevalence rates ranging from 2% to 17%[131]. Poor concordance of test results between the Wantai, Dia.Pro and MP Diagnostics HEV enzyme-linked immunosorbent assays (ELISA) were observed[132,133]. This may partly explain the broad ranges of anti-HEV IgG prevalence (5.3% to 48.9%) reported in Italy[55,56,92-94].In contrast, most studies conducted in China used the Wantai assay and revealed a similar seroprevalence of around 20% to 30%. This assay is believed to be more sensitive than other commercial assays in detecting anti-HEV IgG[134,135].

**TRANSFUSION-TRANSMITTED HEPATITIS E**

HEV transmission *via* transfusion has been reported since 2004[136] and there has been increasing recognition of the risk of transmitting HEV by transfusion in recent years. Cases of TT-HEV are shown in Table 4[137-150].Identical genomic sequences were identified in most infected patients and blood donors. Table 4 Likely only represents the tip of the iceberg as other probable or possible cases have been reported in the literature[151,152]. At the same time, patients with mild symptoms of hepatitis E may have gone undiagnosed. Physicians should stay vigilant for HEV infection in patients who have received a blood transfusion.

Although blood components that contain larger plasma volumes, principally fresh frozen plasma and platelet components, are believed to transmit HEV more readily[64], a number of TT-HEV cases associated with red blood cell transfusion have also been described[138,140,141,143,144,148-150]. Red blood cell transfusion was a significant risk factor for HEV seropositivity in patients on hemodialysis in Croatia[153]. Twenty percent (*n* = 8/40) of multiply transfused thalassemia patients were anti-HEV IgG positive compared with 11.0% (*n* = 10/91) in blood donors[154]. In contrast, a study in Iran found anti-HEV antibodies in only 1.67% of patients with thalassemia, suggesting a low rate of TT-HEV in that country[155]. Results from these two studies in thalassemia patients were limited by the small sample size. Ankcorn *et al*[156] analyzed 1591 patients with hematologic malignancy and found that the more transfusions of non-HEV screened blood products the patients had received, the higher their likelihood of being IgG seroreactive was, suggesting HEV acquisition *via* transfusion in these patients.

A study by Hewitt *et al*[64] indicated that a viral concentration of between 407 and 257039 IU/mL in blood products was associated with TT-HEV, and that a high viral load in donors rendered infection more likely (*P* < 0.0001). However, this may not be true in immunocompromised patients. In a systematic review, Dreier *et al*[50] calculated the median transfused viral load in HEV-infected and non-infected immunocompromised patients. Although the transfused viral load was higher in the infected than the non-infected individuals (4.80 × 105 IU *vs* 1.55 × 104 IU), the between-group difference was not statistically significant (*P* = 0.1006)[50]. A potential reason for this finding is that a low viral concentration (150 IU/mL) of the blood component could already be infectious[140].

Most cases of TT-HEV occur in immunocompromised recipients, such as patients with hematologic malignancies, or recipients of solid organ or hematopoietic stem cell transplants. However, patients on simple immunosuppressants like corticosteroidsand cyclosporine or even immunocompetent individuals are also at risk[157]. Massive transfusion increased the risk of HEV transmission in an immunocompetent trauma patient[158]. Spontaneous resolution, viral eradication by immunosuppressant reduction and/or ribavirin are possible[159] but occasionally there are cases which have progressed into chronic hepatitis, liver cirrhosis or multi-organ failure. Transfusion recipients are more vulnerable to chronic liver injury than the general population as a result of foodborne infection[140]. More than 60% (*n* = 56/85) of solid organ transplant recipients infected with HEV developed chronic hepatitis, with tacrolimus use as an independent predictive factor[160]. Pas *et al*[161] screened 1200 solid-organ transplant recipients in the Netherlands for HEV RNA and identified 12 patients with HEV infection. Nine of these 12 patients had been treated with a tacrolimus-based regimen postoperatively. In liver transplant recipients, graft hepatitis with rapid histological disease progression and requirement of re-transplantation due to liver cirrhosis has been reported[162,163]. The rapid progression of HEV infection to advanced fibrosis and cirrhosis has also been observed in individuals receiving kidney or heart transplants[33].In 50 patients with hematologic malignancy and clinically overt hepatitis E, the mortality rate was 16% (*n* = 8), with liver-related death occurring in 4 patients[164]. HEV could actively suppress the cellular immune response and increase levels of immunosuppressive interleukin-10 that may perpetuate chronic infection and subsequent liver damage[165,166].

**TREATMENT**

The management strategy for HEV infection should be determined by the clinical presentation. Currently, there is limited information in the published literature that describes the clinical features of TT-HEV, or the optimal approach to management. Acute TT-HEV infections are usually subclinical or mild, with no severe or fulminant cases reported[140]. Therefore, most acute HEV infections should be treated conservatively, while waiting for spontaneous clearance, although a short course of ribavirin may also be considered. In 21 patients with acute HEV infection who were at high risk of liver failure, receiving immunosuppressive therapy for an autoimmune disease or undergoing chemotherapy, a short course of ribavirin for up to 3 mo was associated with rapid virological response and normalization of liver enzymes[167].

The current practice for management of chronic HEV infection is mainly based on observational data[18]; Figure 1 shows a proposed algorithm for management. In patients who are on immunosuppressants, the first-line intervention should be a dose reduction or discontinuation of the immunosuppressive drug[168,169]. In solid organ transplant recipients, reducing the dose of immunosuppressive therapies that principally target T-cells can achieve HEV clearance in nearly one third of patients[160]. Most immunosuppressive drugs such as cyclosporine and tacrolimus increase HEV replication in vitro; mycophenolate mofetil is the only immunosuppressant agent demonstrated to have an anti-viral effect[170].

If modification of the immunosuppressant regimen is not possible or is unsuccessful, pharmacological agents such as ribavirin and/or pegylated interferon-alpha (peg-IFN) can be used[171]. In a meta-analysis that included 395 patients with chronic hepatitis E, ribavirin monotherapy for a median of 3 mo achieved sustained virological response (SVR) in 76% of patients[172]. The reported dose of ribavirin in the literature ranged from 29 to 1200 mg/d, and the duration from 1 to 18 mo. Data on the optimal treatment regimen are needed[173]. HEV RNA should be assessed in the serum and in the stool before treatment discontinuation[169]. A second course of ribavirin for 6 mo can be attempted in cases of treatment failure[172]. HEV RNA concentrations decrease within the first week of initiating ribavirin therapy, and a greater reduction in viral load on day 7 is an independent predictor of SVR[174]. Ribavirin failure has been linked to the presence of certain single nucleotide variants (SNVs) and in-frame insertions in the hypervariable region of open reading frame (ORF) 1 in the HEV genome[175].

For those who are refractory to, or intolerant of, ribavirin, peg-IFN can be considered. Its efficacy has been documented in patients with hematologic disorders, patients receiving hemodialysis, and in combination with ribavirin in patients with HIV[176-178]. Close monitoring is needed if it is used in transplant recipients because of an increased risk of acute humoral and cellular rejection[179,180]. Peg-IFN was thought to be safe only in liver transplant recipients until recent case reports described its successful use in a kidney transplant recipient[181-183].

Sofosbuvir is a nucleotide analog shown to decrease replication of HEV-3 *in vitro*[184]. However, in clinical studies, only modest antiviral activity was observed and SVR was not achieved[185-187]. Rescue treatment for patients who are not eligible for, or not responding to, ribavirin and/or peg-IFN remains an unmet need.

**HOW TO REDUCE TRANSFUSION-TRANSMITTED HEPATITIS E**

The background risk of foodborne HEV transmission to both donors and recipients of blood products is not negligible. The transfusion-related risk of infection only exceeds the annual dietary risk when more than 13 individual donor components are transfused[188]. Strategies to reduce *de novo* infection, such as modifying eating habits and eliminating HEV from pigs and other animals that are used for food production are essential[189]. The one available vaccine (HEV 239, Hecolin, Xiamen, China) is licensed only in China, and has yet to play a fundamental role in global outbreaks or pandemic control[190]. Nonetheless, the transmissibility and disease phenotype may not be the same for a person who acquires the virus orally and a person who gets infected intravenously, as there may be some protection provided by the acidic environment of the stomach and the mucosal barrier in the gut[191]. The infectivity of the non-enveloped form is different to that of enveloped HEV[9]. Data reporting outcomes of recipients of HEV-infected blood products are sparse[47,49,50,60,64].

Policies on screening HEV in blood products differ between countries. Universal screening was adopted in the United Kingdom, Ireland, and the Netherlands. Germany and France implemented targeted screening of donated plasma intended for use in high-risk patients[192]. In Japan, the use of nucleic acid-based screening is limited to Hokkaido[193]. Blood donors are not routinely tested for HEV infection in China including Hong Kong[70,71,194]. There has been much debate on mandatory HEV screening in blood donations[195]. Key questions, such as whether or not to screen, which laboratory assay to use, which donors to screen (universal or selective screening), and which types of blood components to screen should be assessed based on risk assessment, resource availability, health economics, and political or other influences. The answers may vary considerably by geographical location[169,196]. In areas where HEV is highly endemic, most donors and/or recipients have probably been exposed to HEV previously and would have positive IgG antibodies. Therefore, the decision on serological screening should also take into consideration the prevalence of HEV infection in that particular region.

All donors should answer a questionnaire about symptoms of clinical hepatitis and potential exposure to HEV prior to blood donation. Donation should be deferred in any donors with a history of clinical hepatitis[197]. Neither alanine aminotransferase (ALT) nor anti-HEV IgM testing correlate with the presence of HEV RNA, supporting the use of NAT for screening of blood donations[60,61,105].A simulation study by Kamp *et al*[198] reported that testing for HEV RNA by NAT with a pool size of 96, and a 95% limit of detection of 20 IU/mL will result in an 80% reduction in expected HEV transmissions as well as of consequent chronic infections with severe complications. The risk of transmission could be reduced by 90% in NAT using a mini-pool of 24 samples[198].

If opting for selective screening instead of universal screening, a clear definition of at-risk patients is warranted[199]. Targeted screening should be contemplated for blood components that will be supplied to transplant recipients, or patients with hematologic malignancies or chronic liver disease, as these individuals are at high risk of developing fulminant hepatitis, acute on chronic liver failure, or chronic hepatitis. However, it is not yet clear whether patients with rheumatologic diseases, those on low-intensity immunosuppression, or elderly individuals should only receive HEV-negative blood products. A multicenter retrospective study in Europe including 21 rheumatology and internal medicine patients found that patients with rheumatoid arthritis who were receiving methotrexate or biologics were at risk of chronic hepatitis E infection[200]. However, another study in France did not find worse hepatitis E severity or increased risk of chronicity in 23 patients with inflammatory arthritis treated with immunosuppressants[201].

Patients co-infected with HIV with CD4+ count < 200/mm3 are at risk for persistent HEV infection[29].In HIV patients with low CD4+ count, anti-HEV IgG seroconversion was delayed until immune reconstitution occurred[202]. A recent meta-analysis found that the HEV RNA positivity rate was significantly higher in transplant recipients than in HIV-positive patients [1.2% (95%CI: 0.9-1.6) *vs* 0.39% (95%CI: 0.2-0.7); *P* = 0.0011], possibly due to better immune status in the HIV-positive individuals using anti-retroviral therapy[203].

HEV-1 and -2 infections can take a fulminant course in pregnancy, resulting in liver failure, membrane rupture, spontaneous abortions, and stillbirths[204]. HEV-3 infection in pregnancy appears to be less virulent without significant maternal, fetal, or neonatal complications[205-207]. During pregnancy, a reduced cellular immunity and a high level of steroid hormones, in particular estrogen, progesterone, and human chorionic gonadotropin, influence viral replication/expression and possibly explain the disease severity[208]. The immune response could be influenced by HEV genotype, translating into different outcomes[209]. Ribavirin and peg-IFN are contraindicated in pregnancy due to concerns of teratogenicity[210]. Further studies are needed to clarify the risk of transmission of HEV to pregnant women *via* blood transfusion; however, in view of the potentially serious disease course and absence of a safe treatment, pregnant women are a priority group for HEV-negative blood products.

Roth *et al*[67] evaluated the safety of plasma-derived medicinal products (PDMP) and found a very low prevalence of HEV RNA (0.002%) in plasma donors. Since viral reduction methods are used in the manufacturing processes of PDMP, these data do not support routine screening of all plasma pools intended for producing PDMP. Currently there is a lack of evidence to suggest that human serum albumin or coagulation factor concentrates are a major source of HEV infection[211,212].

The cost effectiveness of HEV screening of blood donations was analyzed in the Netherlands. Screening of whole blood donations in pools of 24 would prevent 4.52 of the 4.94 TT-HEV infections annually at a cost of approximately €310000 (Euro) per prevented chronic case. The estimated cost per incurable case prevented was 10-fold higher. Costs could potentially be reduced by 85% if only the blood products intended for use by immunocompromised patients were screened. Additional costs for selective screening may arise for logistic reasons and a possible increase in the number of blood products that expire before use. They concluded that preventing HEV transmission by screening of blood donations appears not excessively expensive compared with other blood-screening measures but the impact on disease burden may be small as only a minority of all HEV cases are transmitted by blood transfusion[213]. Another economic analysis performed in North America found a very low estimated risk of TT-HEV infection risk leading to severe liver disease. When compared with no screening, the costs were $2.68 (USD) per component for a selective screening approach, and $6.68 per component for universal screening. The respective costs per quality-adjusted life-year gained were $225546 and $561810, respectively, which exceeded the threshold for what is considered as “cost-effective”[66].

In addition to screening, various pathogen reduction methods have been proposed to reduce risk of TT-HEV. Solvent/detergent treatment could not eliminate non-enveloped HEV in plasma[214]. Non-enveloped HEV is also resistant to the Intercept method, which combines a synthetic psoralen amotosalen HCl treatment with ultraviolet A light illumination to block the replication of DNA and RNA[215]. However, substantial viral reduction has been demonstrated during the manufacturing process of plasma products using immunoaffinity chromatography, nanofiltration, cold ethanol fractionation and heat treatment[216]. Anti-HEV antibodies enhanced HEV removal by nanofiltration[217]. Furthermore, ultraviolet C light provided effective inactivation of HEV in platelet concentrates[218].

**CONCLUSION**

To conclude, TT-HEV is gaining attention worldwide. Although the overall prevalence of viremic blood donations is low, HEV can cause sinister consequences in immunocompromised recipients. Future studies are needed to define the incidence of transmission through transfusion, clinical features, outcomes, and prognosis. The decision on a screening policy in asymptomatic blood donors should be based on local risk assessment and health economics.

**REFERENCES**

1 **Khuroo MS**. Chronic liver disease after non-A, non-B hepatitis. *Lancet* 1980; **2**: 860-861 [PMID: 6107528]

2 **World Health Organization.** Hepatitis E Fact sheet [DOI: 10.1097/grh.0000000000000052]

3 **Li P**, Liu J, Li Y, Su J, Ma Z, Bramer WM, Cao W, de Man RA, Peppelenbosch MP, Pan Q. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. *Liver Int* 2020; **40**: 1516-1528 [PMID: 32281721 DOI: 10.1111/liv.14468]

4 **Wallace SJ**, Swann R, Donnelly M, Kemp L, Guaci J, Murray A, Spoor J, Lin N, Miller M, Dalton HR, Hussaini SH, Gunson R, Simpson K, Stanley A, Fraser A. Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retrospective study. *Aliment Pharmacol Ther* 2020; **51**: 974-986 [PMID: 32285976 DOI: 10.1111/apt.15704]

5 **Bergløv A**, Hallager S, Weis N. Hepatitis E during pregnancy: Maternal and foetal case-fatality rates and adverse outcomes-A systematic review. *J Viral Hepat* 2019; **26**: 1240-1248 [PMID: 31095813 DOI: 10.1111/jvh.13129]

6 **Purdy MA**, Harrison TJ, Jameel S, Meng XJ, Okamoto H, Van der Poel WHM, Smith DB, Ictv Report Consortium. ICTV Virus Taxonomy Profile: Hepeviridae. *J Gen Virol* 2017; **98**: 2645-2646 [PMID: 29022866 DOI: 10.1099/jgv.0.000940]

7 **Primadharsini PP**, Nagashima S, Okamoto H. Genetic Variability and Evolution of Hepatitis E Virus. *Viruses* 2019; **11** [PMID: 31109076 DOI: 10.3390/v11050456]

8 **Sridhar S**, Yip CC, Wu S, Chew NF, Leung KH, Chan JF, Zhao PS, Chan WM, Poon RW, Tsoi HW, Cai JP, Chan HS, Leung AW, Tse CW, Zee JS, Tsang OT, Cheng VC, Lau SK, Woo PC, Tsang DN, Yuen KY. Transmission of Rat Hepatitis E Virus Infection to Humans in Hong Kong: A Clinical and Epidemiological Analysis. *Hepatology* 2021; **73**: 10-22 [PMID: 31960460 DOI: 10.1002/hep.31138]

9 **Yin X**, Ambardekar C, Lu Y, Feng Z. Distinct Entry Mechanisms for Nonenveloped and Quasi-Enveloped Hepatitis E Viruses. *J Virol* 2016; **90**: 4232-4242 [PMID: 26865708 DOI: 10.1128/JVI.02804-15]

10 **Himmelsbach K**, Bender D, Hildt E. Life cycle and morphogenesis of the hepatitis E virus. *Emerg Microbes Infect* 2018; **7**: 196 [PMID: 30498191 DOI: 10.1038/s41426-018-0198-7]

11 **Kenney SP**, Meng XJ. Hepatitis E Virus Genome Structure and Replication Strategy. *Cold Spring Harb Perspect Med* 2019; **9** [PMID: 29530948 DOI: 10.1101/cshperspect.a031724]

12 **Kmush B**, Wierzba T, Krain L, Nelson K, Labrique AB. Epidemiology of hepatitis E in low- and middle-income countries of Asia and Africa. *Semin Liver Dis* 2013; **33**: 15-29 [PMID: 23564386 DOI: 10.1055/s-0033-1338111]

13 **Khuroo MS**, Khuroo MS, Khuroo NS. Hepatitis E: Discovery, global impact, control and cure. *World J Gastroenterol* 2016; **22**: 7030-7045 [PMID: 27610014 DOI: 10.3748/wjg.v22.i31.7030]

14 **Rein DB**, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. *Hepatology* 2012; **55**: 988-997 [PMID: 22121109 DOI: 10.1002/hep.25505]

15 **Hakze-van der Honing RW**, van Coillie E, Antonis AF, van der Poel WH. First isolation of hepatitis E virus genotype 4 in Europe through swine surveillance in the Netherlands and Belgium. *PLoS One* 2011; **6**: e22673 [PMID: 21829641 DOI: 10.1371/journal.pone.0022673]

16 **Garbuglia AR**, Scognamiglio P, Petrosillo N, Mastroianni CM, Sordillo P, Gentile D, La Scala P, Girardi E, Capobianchi MR. Hepatitis E virus genotype 4 outbreak, Italy, 2011. *Emerg Infect Dis* 2013; **19**: 110-114 [PMID: 23260079 DOI: 10.3201/eid1901.120983]

17 **Donnelly MC**, Scobie L, Crossan CL, Dalton H, Hayes PC, Simpson KJ. Review article: hepatitis E-a concise review of virology, epidemiology, clinical presentation and therapy. *Aliment Pharmacol Ther* 2017; **46**: 126-141 [PMID: 28449246 DOI: 10.1111/apt.14109]

18 **Goel A**, Aggarwal R. Hepatitis E: Epidemiology, Clinical Course, Prevention, and Treatment. *Gastroenterol Clin North Am* 2020; **49**: 315-330 [PMID: 32389365 DOI: 10.1016/j.gtc.2020.01.011]

19 **Kamar N**, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, Dalton HR. Hepatitis E virus infection. *Nat Rev Dis Primers* 2017; **3**: 17086 [PMID: 29154369 DOI: 10.1038/nrdp.2017.86]

20 **Dalton HR**, Stableforth W, Thurairajah P, Hazeldine S, Remnarace R, Usama W, Farrington L, Hamad N, Sieberhagen C, Ellis V, Mitchell J, Hussaini SH, Banks M, Ijaz S, Bendall RP. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. *Eur J Gastroenterol Hepatol* 2008; **20**: 784-790 [PMID: 18617784 DOI: 10.1097/MEG.0b013e3282f5195a]

21 **Lhomme S**, Marion O, Abravanel F, Izopet J, Kamar N. Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. *J Clin Med* 2020; **9** [PMID: 31991629 DOI: 10.3390/jcm9020331]

22 **Haffar S**, Shalimar, Kaur RJ, Wang Z, Prokop LJ, Murad MH, Bazerbachi F. Acute liver failure caused by hepatitis E virus genotype 3 and 4: A systematic review and pooled analysis. *Liver Int* 2018; **38**: 1965-1973 [PMID: 29675889 DOI: 10.1111/liv.13861]

23 **Smith DB**, Simmonds P. Hepatitis E virus and fulminant hepatitis--a virus or host-specific pathology? *Liver Int* 2015; **35**: 1334-1340 [PMID: 24974734 DOI: 10.1111/liv.12629]

24 **Frias M**, López-López P, Rivero A, Rivero-Juarez A. Role of Hepatitis E Virus Infection in Acute-on-Chronic Liver Failure. *Biomed Res Int* 2018; **2018**: 9098535 [PMID: 30050945 DOI: 10.1155/2018/9098535]

25 **Radha Krishna Y**, Saraswat VA, Das K, Himanshu G, Yachha SK, Aggarwal R, Choudhuri G. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. *Liver Int* 2009; **29**: 392-398 [PMID: 19267864 DOI: 10.1111/j.1478-3231.2008.01887.x]

26 **Kamar N**, Rostaing L, Legrand-Abravanel F, Izopet J. How should hepatitis E virus infection be defined in organ-transplant recipients? *Am J Transplant* 2013; **13**: 1935-1936 [PMID: 23659713 DOI: 10.1111/ajt.12253]

27 **Pischke S**, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, Ganzenmueller T, Schlue J, Horn-Wichmann R, Raupach R, Darnedde M, Scheibner Y, Taubert R, Haverich A, Manns MP, Wedemeyer H, Bara CL. Chronic hepatitis e in heart transplant recipients. *Am J Transplant* 2012; **12**: 3128-3133 [PMID: 22823202 DOI: 10.1111/j.1600-6143.2012.04200.x]

28 **Ollier L**, Tieulie N, Sanderson F, Heudier P, Giordanengo V, Fuzibet JG, Nicand E. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. *Ann Intern Med* 2009; **150**: 430-431 [PMID: 19293084 DOI: 10.7326/0003-4819-150-6-200903170-00026]

29 **Dalton HR**, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. *N Engl J Med* 2009; **361**: 1025-1027 [PMID: 19726781 DOI: 10.1056/NEJMc0903778]

30 **Sridhar S**, Chan JFW, Yap DYH, Teng JLL, Huang C, Yip CCY, Hung IFN, Tang SCW, Lau SKP, Woo PCY, Yuen KY. Genotype 4 hepatitis E virus is a cause of chronic hepatitis in renal transplant recipients in Hong Kong. *J Viral Hepat* 2018; **25**: 209-213 [PMID: 28984015 DOI: 10.1111/jvh.12799]

31 **Wang Y**, Chen G, Pan Q, Zhao J. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient. *Gastroenterology* 2018; **154**: 1199-1201 [PMID: 29432746 DOI: 10.1053/j.gastro.2017.12.028]

32 **Owada Y**, Oshiro Y, Inagaki Y, Harada H, Fujiyama N, Kawagishi N, Yagisawa T, Usui J, Akutsu N, Itabashi Y, Saito K, Watarai Y, Ichimaru N, Imamura R, Kyakuno M, Ide K, Shibuya Y, Okabe Y, Ono M, Sasaki K, Shiose A, Yamagishi K, Ohnishi H, Nagashima S, Takahashi M, Yuzawa K, Okamoto H, Ohkohchi N. A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis in Heart and Kidney Transplant Recipients in Japan. *Transplantation* 2020; **104**: 437-444 [PMID: 31205267 DOI: 10.1097/TP.0000000000002801]

33 **Zhou X**, de Man RA, de Knegt RJ, Metselaar HJ, Peppelenbosch MP, Pan Q. Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. *Rev Med Virol* 2013; **23**: 295-304 [PMID: 23813631 DOI: 10.1002/rmv.1751]

34 **Mirazo S**, Arbiza J. Hepatitis E and chronic liver damage in apparently immunocompetent individuals: Now what? *Ann Hepatol* 2019; **18**: 539-540 [PMID: 31130468 DOI: 10.1016/j.aohep.2019.05.002]

35 **Protzer U**, Böhm F, Longerich T, Seebach J, Heidary Navid M, Friemel J, Marques-Maggio E, Bawohl M, Heikenwalder M, Schirmacher P, Dutkowski P, Clavien PA, Schemmer P, Schnitzler P, Gotthardt D, Müllhaupt B, Weber A. Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation. *Mod Pathol* 2015; **28**: 523-532 [PMID: 25412844 DOI: 10.1038/modpathol.2014.147]

36 **Suneetha PV**, Pischke S, Schlaphoff V, Grabowski J, Fytili P, Gronert A, Bremer B, Markova A, Jaroszewicz J, Bara C, Manns MP, Cornberg M, Wedemeyer H. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. *Hepatology* 2012; **55**: 695-708 [PMID: 22006345 DOI: 10.1002/hep.24738]

37 **Borentain P**, Colson P, Bolon E, Gauchez P, Coso D, Gérolami R. Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis. *Hepatology* 2018; **67**: 446-448 [PMID: 28873236 DOI: 10.1002/hep.29508]

38 **Pischke S**, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA. Hepatitis E virus: Infection beyond the liver? *J Hepatol* 2017; **66**: 1082-1095 [PMID: 27913223 DOI: 10.1016/j.jhep.2016.11.016]

39 **Fousekis FS**, Mitselos IV, Christodoulou DK. Extrahepatic manifestations of hepatitis E virus: An overview. *Clin Mol Hepatol* 2020; **26**: 16-23 [PMID: 31601068 DOI: 10.3350/cmh.2019.0082]

40 **Kamar N**, Weclawiak H, Guilbeau-Frugier C, Legrand-Abravanel F, Cointault O, Ribes D, Esposito L, Cardeau-Desangles I, Guitard J, Sallusto F, Muscari F, Peron JM, Alric L, Izopet J, Rostaing L. Hepatitis E virus and the kidney in solid-organ transplant patients. *Transplantation* 2012; **93**: 617-623 [PMID: 22298032 DOI: 10.1097/TP.0b013e318245f14c]

41 **Noble J**, Jouve T, Malvezzi P, Rostaing L. Renal complications of liver diseases. *Expert Rev Gastroenterol Hepatol* 2018; **12**: 1135-1142 [PMID: 30269605 DOI: 10.1080/17474124.2018.1530984]

42 **Kamar N**, Marion O, Abravanel F, Izopet J, Dalton HR. Extrahepatic manifestations of hepatitis E virus. *Liver Int* 2016; **36**: 467-472 [PMID: 27005692 DOI: 10.1111/liv.13037]

43 **Liu H**, Ma Y. Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature. *Brain Behav* 2020; **10**: e01496 [PMID: 31828968 DOI: 10.1002/brb3.1496]

44 **Ripellino P**, Pasi E, Melli G, Staedler C, Fraga M, Moradpour D, Sahli R, Aubert V, Martinetti G, Bihl F, Bernasconi E, Terziroli Beretta-Piccoli B, Cerny A, Dalton HR, Zehnder C, Mathis B, Zecca C, Disanto G, Kaelin-Lang A, Gobbi C. Neurologic complications of acute hepatitis E virus infection. *Neurol Neuroimmunol Neuroinflamm* 2020; **7** [PMID: 31806684 DOI: 10.1212/NXI.0000000000000643]

45 **Fischer C**, Hofmann M, Danzer M, Hofer K, Kaar J, Gabriel C. Seroprevalence and Incidence of hepatitis E in blood donors in Upper Austria. *PLoS One* 2015; **10**: e0119576 [PMID: 25751574 DOI: 10.1371/journal.pone.0119576]

46 **Vercouter AS**, Van Houtte F, Verhoye L, González Fraile I, Blanco L, Compernolle V, Meuleman P. Hepatitis E virus prevalence in Flemish blood donors. *J Viral Hepat* 2019; **26**: 1218-1223 [PMID: 31194897 DOI: 10.1111/jvh.13161]

47 **Harritshøj LH**, Holm DK, Saekmose SG, Jensen BA, Hogema BM, Fischer TK, Midgley SE, Krog JS, Erikstrup C, Ullum H. Low transfusion transmission of hepatitis E among 25,637 single-donation, nucleic acid-tested blood donors. *Transfusion* 2016; **56**: 2225-2232 [PMID: 27385646 DOI: 10.1111/trf.13700]

48 **Gallian P**, Lhomme S, Piquet Y, Sauné K, Abravanel F, Assal A, Tiberghien P, Izopet J. Hepatitis E virus infections in blood donors, France. *Emerg Infect Dis* 2014; **20**: 1914-1917 [PMID: 25340881 DOI: 10.3201/eid2011.140516]

49 **Westhölter D**, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Blöcker J, Schulze Zur Wiesch J, Fischer N, Addo MM, Peine S, Göke B, Lohse AW, Lütgehetmann M, Pischke S. HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients. *J Hepatol* 2018; **69**: 36-42 [PMID: 29551705 DOI: 10.1016/j.jhep.2018.02.031]

50 **Dreier J**, Knabbe C, Vollmer T. Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose. *Front Med (Lausanne)* 2018; **5**: 5 [PMID: 29450199 DOI: 10.3389/fmed.2018.00005]

51 **Corman VM**, Drexler JF, Eckerle I, Roth WK, Drosten C, Eis-Hübinger AM. Zoonotic hepatitis E virus strains in German blood donors. *Vox Sang* 2013; **104**: 179-180 [PMID: 22913247 DOI: 10.1111/j.1423-0410.2012.01638.x]

52 **Vollmer T**, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J. Novel approach for detection of hepatitis E virus infection in German blood donors. *J Clin Microbiol* 2012; **50**: 2708-2713 [PMID: 22675127 DOI: 10.1128/JCM.01119-12]

53 **Baylis SA**, Gärtner T, Nick S, Ovemyr J, Blümel J. Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. *Vox Sang* 2012; **103**: 89-90 [PMID: 22220775 DOI: 10.1111/j.1423-0410.2011.01583.x]

54 **O'Riordan J**, Boland F, Williams P, Donnellan J, Hogema BM, Ijaz S, Murphy WG. Hepatitis E virus infection in the Irish blood donor population. *Transfusion* 2016; **56**: 2868-2876 [PMID: 27522065 DOI: 10.1111/trf.13757]

55 **Spreafico M**, Raffaele L, Guarnori I, Foglieni B, Berzuini A, Valenti L, Gerosa A, Colli A, Prati D. Prevalence and 9-year incidence of hepatitis E virus infection among North Italian blood donors: Estimated transfusion risk. *J Viral Hepat* 2020; **27**: 858-861 [PMID: 32196831 DOI: 10.1111/jvh.13296]

56 **Spada E**, Pupella S, Pisani G, Bruni R, Chionne P, Madonna E, Villano U, Simeoni M, Fabi S, Marano G, Marcantonio C, Pezzotti P, Ciccaglione AR, Liumbruno GM. A nationwide retrospective study on prevalence of hepatitis E virus infection in Italian blood donors. *Blood Transfus* 2018; **16**: 413-421 [PMID: 29757135 DOI: 10.2450/2018.0033-18]

57 **Hogema BM**, Molier M, Sjerps M, de Waal M, van Swieten P, van de Laar T, Molenaar-de Backer M, Zaaijer HL. Incidence and duration of hepatitis E virus infection in Dutch blood donors. *Transfusion* 2016; **56**: 722-728 [PMID: 26559806 DOI: 10.1111/trf.13402]

58 **Slot E**, Hogema BM, Riezebos-Brilman A, Kok TM, Molier M, Zaaijer HL. Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. *Euro Surveill* 2013; **18** [PMID: 23929229 DOI: 10.2807/1560-7917.es2013.18.31.20550]

59 **Grabarczyk P**, Sulkowska E, Gdowska J, Kopacz A, Liszewski G, Kubicka-Russel D, Baylis SA, Corman VM, Noceń E, Piotrowski D, Antoniewicz-Papis J, Łętowska M. Molecular and serological infection marker screening in blood donors indicates high endemicity of hepatitis E virus in Poland. *Transfusion* 2018; **58**: 1245-1253 [PMID: 29492976 DOI: 10.1111/trf.14531]

60 **Rivero-Juarez A**, Jarilla-Fernandez M, Frias M, Madrigal-Sanchez E, López-López P, Andújar-Troncoso G, Machuca I, Camacho A, Muñoz-Valbuena P, Rivero A. Hepatitis E virus in Spanish donors and the necessity for screening. *J Viral Hepat* 2019; **26**: 603-608 [PMID: 30661278 DOI: 10.1111/jvh.13064]

61 **Sauleda S**, Ong E, Bes M, Janssen A, Cory R, Babizki M, Shin T, Lindquist A, Hoang A, Vang L, Piron M, Casamitjana N, Koppelman M, Danzig L, Linnen JM. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). *Transfusion* 2015; **55**: 972-979 [PMID: 25403913 DOI: 10.1111/trf.12929]

62 **Harvala H**, Hewitt PE, Reynolds C, Pearson C, Haywood B, Tettmar KI, Ushiro-Lumb I, Brailsford SR, Tedder R, Ijaz S. Hepatitis E virus in blood donors in England, 2016 to 2017: from selective to universal screening. *Euro Surveill* 2019; **24** [PMID: 30862338 DOI: 10.2807/1560-7917.ES.2019.24.10.1800386]

63 **Thom K**, Gilhooly P, McGowan K, Malloy K, Jarvis LM, Crossan C, Scobie L, Blatchford O, Smith-Palmer A, Donnelly MC, Davidson JS, Johannessen I, Simpson KJ, Dalton HR, Petrik J. Hepatitis E virus (HEV) in Scotland: evidence of recent increase in viral circulation in humans. *Euro Surveill* 2018; **23** [PMID: 29589577 DOI: 10.2807/1560-7917.ES.2018.23.12.17-00174]

64 **Hewitt PE**, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, Kennedy IT, Kitchen A, Patel P, Poh J, Russell K, Tettmar KI, Tossell J, Ushiro-Lumb I, Tedder RS. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. *Lancet* 2014; **384**: 1766-1773 [PMID: 25078306 DOI: 10.1016/S0140-6736(14)61034-5]

65 **Cleland A**, Smith L, Crossan C, Blatchford O, Dalton HR, Scobie L, Petrik J. Hepatitis E virus in Scottish blood donors. *Vox Sang* 2013; **105**: 283-289 [PMID: 23763589 DOI: 10.1111/vox.12056]

66 **Delage G**, Fearon M, Gregoire Y, Hogema BM, Custer B, Scalia V, Hawes G, Bernier F, Nguyen ML, Stramer SL. Hepatitis E Virus Infection in Blood Donors and Risk to Patients in the United States and Canada. *Transfus Med Rev* 2019; **33**: 139-145 [PMID: 31324552 DOI: 10.1016/j.tmrv.2019.05.017]

67 **Roth NJ**, Schäfer W, Alexander R, Elliott K, Elliott-Browne W, Knowles J, Wenzel JJ, Simon TL. Low hepatitis E virus RNA prevalence in a large-scale survey of United States source plasma donors. *Transfusion* 2017; **57**: 2958-2964 [PMID: 28833188 DOI: 10.1111/trf.14285]

68 **Stramer SL**, Moritz ED, Foster GA, Ong E, Linnen JM, Hogema BM, Mak M, Chia CP, Dodd RY. Hepatitis E virus: seroprevalence and frequency of viral RNA detection among US blood donors. *Transfusion* 2016; **56**: 481-488 [PMID: 26434952 DOI: 10.1111/trf.13355]

69 **Xu C**, Wang RY, Schechterly CA, Ge S, Shih JW, Xia NS, Luban NL, Alter HJ. An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. *Transfusion* 2013; **53**: 2505-2511 [PMID: 23829163 DOI: 10.1111/trf.12326]

70 **Wen GP**, Chen CR, Song XY, Tang ZM, Ji WF, Wang SL, Zhang K, Zhang J, Ou SH, Zheng ZZ, Xia NS. Long-term HEV carriers without antibody seroconversion among eligible immunocompetent blood donors. *Emerg Microbes Infect* 2018; **7**: 125 [PMID: 29977038 DOI: 10.1038/s41426-018-0125-y]

71 **Tsoi WC**, Zhu X, To AP, Holmberg J. Hepatitis E virus infection in Hong Kong blood donors. *Vox Sang* 2020; **115**: 11-17 [PMID: 31709559 DOI: 10.1111/vox.12846]

72 **Katiyar H**, Goel A, Sonker A, Yadav V, Sapun S, Chaudhary R, Aggarwal R. Prevalence of hepatitis E virus viremia and antibodies among healthy blood donors in India. *Indian J Gastroenterol* 2018; **37**: 342-346 [PMID: 30159666 DOI: 10.1007/s12664-018-0880-7]

73 **Minagi T**, Okamoto H, Ikegawa M, Ideno S, Takahashi K, Sakai K, Hagiwara K, Yunoki M, Wakisaka A. Hepatitis E virus in donor plasma collected in Japan. *Vox Sang* 2016; **111**: 242-246 [PMID: 27280485 DOI: 10.1111/vox.12425]

74 **Intharasongkroh D**, Thongmee T, Sa-Nguanmoo P, Klinfueng S, Duang-In A, Wasitthankasem R, Theamboonlers A, Charoonruangrit U, Oota S, Payungporn S, Vongpunsawad S, Chirathaworn C, Poovorawan Y. Hepatitis E virus infection in Thai blood donors. *Transfusion* 2019; **59**: 1035-1043 [PMID: 30443992 DOI: 10.1111/trf.15041]

75 **Hoad VC**, Seed CR, Fryk JJ, Harley R, Flower RLP, Hogema BM, Kiely P, Faddy HM. Hepatitis E virus RNA in Australian blood donors: prevalence and risk assessment. *Vox Sang* 2017; **112**: 614-621 [PMID: 28833229 DOI: 10.1111/vox.12559]

76 **Shrestha AC**, Flower RL, Seed CR, Keller AJ, Harley R, Chan HT, Hoad V, Warrilow D, Northill J, Holmberg JA, Faddy HM. Hepatitis E virus RNA in Australian blood donations. *Transfusion* 2016; **56**: 3086-3093 [PMID: 27667133 DOI: 10.1111/trf.13799]

77 **Hewitt J**, Harte D, Sutherland M, Croucher D, Fouche L, Flanagan P, Williamson D. Prevalence of hepatitis E virus antibodies and infection in New Zealand blood donors. *N Z Med J* 2018; **131**: 38-43 [PMID: 29389927]

78 **Maponga TG**, Lopes T, Cable R, Pistorius C, Preiser W, Andersson MI. Prevalence and risks of hepatitis E virus infection in blood donors from the Western Cape, South Africa. *Vox Sang* 2020; **115**: 695-702 [PMID: 32597542 DOI: 10.1111/vox.12966]

79 **Wang M**, Fu P, Yin Y, He M, Liu Y. Acute, Recent and Past HEV Infection among Voluntary Blood Donors in China: A Systematic Review and Meta-Analysis. *PLoS One* 2016; **11**: e0161089 [PMID: 27597991 DOI: 10.1371/journal.pone.0161089]

80 **Di Cola G**, Fantilli AC, Pisano MB, Ré VE. Foodborne transmission of hepatitis A and hepatitis E viruses: A literature review. *Int J Food Microbiol* 2021; **338**: 108986 [PMID: 33257099 DOI: 10.1016/j.ijfoodmicro.2020.108986]

81 **Kamar N**, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, Dalton HR. Hepatitis E. *Lancet* 2012; **379**: 2477-2488 [PMID: 22549046 DOI: 10.1016/S0140-6736(11)61849-7]

82 **Pérez-Gracia MT**, Suay B, Mateos-Lindemann ML. Hepatitis E: an emerging disease. *Infect Genet Evol* 2014; **22**: 40-59 [PMID: 24434240 DOI: 10.1016/j.meegid.2014.01.002]

83 **Gupta N**, Sarangi AN, Dadhich S, Dixit VK, Chetri K, Goel A, Aggarwal R. Acute hepatitis E in India appears to be caused exclusively by genotype 1 hepatitis E virus. *Indian J Gastroenterol* 2018; **37**: 44-49 [PMID: 29399748 DOI: 10.1007/s12664-018-0819-z]

84 **Mevis FM**, Sabeena S, Sanjay R, Robin S, Devadiga S, Prasad V, Oliver D, Ameen A, Arunkumar G. Currently circulating genotypes of hepatitis E virus in India, 2014-2018. *Indian J Med Microbiol* 2019; **37**: 563-568 [PMID: 32436881 DOI: 10.4103/ijmm.IJMM\_19\_449]

85 **Gallian P**, Couchouron A, Dupont I, Fabra C, Piquet Y, Djoudi R, Assal A, Tiberghien P. Comparison of hepatitis E virus nucleic acid test screening platforms and RNA prevalence in French blood donors. *Transfusion* 2017; **57**: 223-224 [PMID: 28097700 DOI: 10.1111/trf.13889]

86 **Vollmer T**, Diekmann J, Knabbe C, Dreier J. Hepatitis E virus blood donor NAT screening: as much as possible or as much as needed? *Transfusion* 2019; **59**: 612-622 [PMID: 30548866 DOI: 10.1111/trf.15058]

87 **Miletić M**, Vuk T, Hećimović A, Stojić Vidović M, Jemeršić L, Jukić I. Estimation of the hepatitis E assay-dependent seroprevalence among Croatian blood donors. *Transfus Clin Biol* 2019; **26**: 229-233 [PMID: 31277986 DOI: 10.1016/j.tracli.2019.06.234]

88 **Holm DK**, Moessner BK, Engle RE, Zaaijer HL, Georgsen J, Purcell RH, Christensen PB. Declining prevalence of hepatitis E antibodies among Danish blood donors. *Transfusion* 2015; **55**: 1662-1667 [PMID: 25819381 DOI: 10.1111/trf.13028]

89 **Dimeglio C**, Beau F, Broult J, Gouy P, Izopet J, Lastère S, Abravanel F. Hepatitis E prevalence in French Polynesian blood donors. *PLoS One* 2018; **13**: e0208934 [PMID: 30532225 DOI: 10.1371/journal.pone.0208934]

90 **Juhl D**, Baylis SA, Blümel J, Görg S, Hennig H. Seroprevalence and incidence of hepatitis E virus infection in German blood donors. *Transfusion* 2014; **54**: 49-56 [PMID: 23441647 DOI: 10.1111/trf.12121]

91 **Dalekos GN**, Zervou E, Elisaf M, Germanos N, Galanakis E, Bourantas K, Siamopoulos KC, Tsianos EV. Antibodies to hepatitis E virus among several populations in Greece: increased prevalence in an hemodialysis unit. *Transfusion* 1998; **38**: 589-595 [PMID: 9661693 DOI: 10.1046/j.1537-2995.1998.38698326339.x]

92 **De Sabato L**, Di Bartolo I, Montomoli E, Trombetta C, Ruggeri FM, Ostanello F. Retrospective Study Evaluating Seroprevalence of Hepatitis E Virus in Blood Donors and in Swine Veterinarians in Italy (2004). *Zoonoses Public Health* 2017; **64**: 308-312 [PMID: 27911040 DOI: 10.1111/zph.12332]

93 **Lucarelli C**, Spada E, Taliani G, Chionne P, Madonna E, Marcantonio C, Pezzotti P, Bruni R, La Rosa G, Pisani G, Dell'Orso L, Ragone K, Tomei C, Ciccaglione AR. High prevalence of anti-hepatitis E virus antibodies among blood donors in central Italy, February to March 2014. *Euro Surveill* 2016; **21** [PMID: 27494608 DOI: 10.2807/1560-7917.ES.2016.21.30.30299]

94 **Puttini C**, Riccio ML, Redi D, Tordini G, Cenerini M, Romanello F, De Luca A, Carmellini M, Fossombroni V, Cusi MG, Zanelli G. Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy. *Infez Med* 2015; **23**: 253-256 [PMID: 26397295]

95 **Hogema BM**, Molier M, Slot E, Zaaijer HL. Past and present of hepatitis E in the Netherlands. *Transfusion* 2014; **54**: 3092-3096 [PMID: 24889277 DOI: 10.1111/trf.12733]

96 **Mateos ML**, Camarero C, Lasa E, Teruel JL, Mir N, Baquero F. Hepatitis E virus: relevance in blood donors and risk groups. *Vox Sang* 1999; **76**: 78-80 [PMID: 10085522 DOI: 10.1159/000031024]

97 **Niederhauser C**, Widmer N, Hotz M, Tinguely C, Fontana S, Allemann G, Borri M, Infanti L, Sarraj A, Sigle J, Stalder M, Thierbach J, Waldvogel S, Wiengand T, Züger M, Gowland P. Current hepatitis E virus seroprevalence in Swiss blood donors and apparent decline from 1997 to 2016. *Euro Surveill* 2018; **23** [PMID: 30180927 DOI: 10.2807/1560-7917.ES.2018.23.35.1700616]

98 **Kaufmann A**, Kenfak-Foguena A, André C, Canellini G, Bürgisser P, Moradpour D, Darling KE, Cavassini M. Hepatitis E virus seroprevalence among blood donors in southwest Switzerland. *PLoS One* 2011; **6**: e21150 [PMID: 21701586 DOI: 10.1371/journal.pone.0021150]

99 **Beale MA**, Tettmar K, Szypulska R, Tedder RS, Ijaz S. Is there evidence of recent hepatitis E virus infection in English and North Welsh blood donors? *Vox Sang* 2011; **100**: 340-342 [PMID: 21392024 DOI: 10.1111/j.1423-0410.2010.01412.x]

100 **Zafrullah M**, Zhang X, Tran C, Nguyen M, Kamili S, Purdy MA, Stramer SL. Disparities in detection of antibodies against hepatitis E virus in US blood donor samples using commercial assays. *Transfusion* 2018; **58**: 1254-1263 [PMID: 29520800 DOI: 10.1111/trf.14553]

101 **Di Lello FA,** Blejer J, Alter A, Bartoli S, Vargas F, Ruiz R, Galli C, Blanco S, Carrizo LH, Gallego S, Fernández R, Martínez AP, Flichman DM. Seroprevalence of hepatitis E virus in Argentinean blood donors. *Eur J Gastroenterol Hepatol* 2020 [DOI: 10.1097/meg.0000000000001853]

102 **Bangueses F**, Abin-Carriquiry JA, Cancela F, Curbelo J, Mirazo S. Serological and molecular prevalence of hepatitis E virus among blood donors from Uruguay. *J Med Virol* 2021; **93**: 4010-4014 [PMID: 32592500 DOI: 10.1002/jmv.26231]

103 **Nouhin J**, Prak S, Madec Y, Barennes H, Weissel R, Hok K, Pavio N, Rouet F. Hepatitis E virus antibody prevalence, RNA frequency, and genotype among blood donors in Cambodia (Southeast Asia). *Transfusion* 2016; **56**: 2597-2601 [PMID: 27480100 DOI: 10.1111/trf.13731]

104 **Chen X**, Gong P, Wagner AL, Li Y, Wang G, Lu Y. Identification of hepatitis E virus subtype 4f in blood donors in Shanghai, China. *Virus Res* 2019; **265**: 30-33 [PMID: 30836112 DOI: 10.1016/j.virusres.2019.03.001]

105 **Wang M**, He M, Wu B, Ke L, Han T, Wang J, Shan H, Ness P, Guo N, Liu Y, Nelson KE. The association of elevated alanine aminotransferase levels with hepatitis E virus infections among blood donors in China. *Transfusion* 2017; **57**: 273-279 [PMID: 28194856 DOI: 10.1111/trf.13991]

106 **Ma L**, Sun P, Lin F, Wang H, Rong X, Dai Y, Liu J, Qian L, Fang M, Su N, Xiao W, Ye S, Li C. Prevalence of hepatitis E virus in Chinese blood donors. *J Int Med Res* 2015; **43**: 257-262 [PMID: 25710945 DOI: 10.1177/0300060514562054]

107 **Ren F**, Zhao C, Wang L, Wang Z, Gong X, Song M, Zhuang H, Huang Y, Shan H, Wang J, Liu Q, Ness P, Nelson KE, Wang Y. Hepatitis E virus seroprevalence and molecular study among blood donors in China. *Transfusion* 2014; **54**: 910-917 [PMID: 24372259 DOI: 10.1111/trf.12530]

108 **Zhuang W**, Ding X, Lyu C, Xiang L, Teng H, Li J. Hepatitis E virus seroprevalence among blood donors in Jiangsu Province, East China. *Int J Infect Dis* 2014; **26**: 9-11 [PMID: 24981426 DOI: 10.1016/j.ijid.2014.04.022]

109 **Tripathy AS**, Puranik S, Sharma M, Chakraborty S, Devakate UR. Hepatitis E virus seroprevalence among blood donors in Pune, India. *J Med Virol* 2019; **91**: 813-819 [PMID: 30489644 DOI: 10.1002/jmv.25370]

110 **Gajjar MD**, Bhatnagar NM, Sonani RV, Gupta S, Patel T. Hepatitis E seroprevalence among blood donors: A pilot study from Western India. *Asian J Transfus Sci* 2014; **8**: 29-31 [PMID: 24678170 DOI: 10.4103/0973-6247.126685]

111 **Parsa R**, Adibzadeh S, Behzad Behbahani A, Farhadi A, Yaghobi R, Rafiei Dehbidi GR, Hajizamani S, Rahbar S, Nikouyan N, Okhovat MA, Naderi S, Salehi S, Alizadeh M, Ranjbaran R, Zarnegar G, Alavi P. Detection of Hepatitis E Virus Genotype 1 Among Blood Donors From Southwest of Iran. *Hepat Mon* 2016; **16**: e34202 [PMID: 27630719 DOI: 10.5812/hepatmon.34202]

112 **Hesamizadeh K**, Sharafi H, Keyvani H, Alavian SM, Najafi-Tireh Shabankareh A, Sharifi Olyaie R, Keshvari M. Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran. *Hepat Mon* 2016; **16**: e32215 [PMID: 27110256 DOI: 10.5812/hepatmon.32215]

113 **Naeimi B**, Mazloom Kalimani F, Pourfatolah AA, Azimzadeh M, Mankhian A, Akbarzadeh S, Hajiani G, Kooshesh F, Khamisipour G. Hepatitis E Virus Seroprevalence Among Blood Donors in Bushehr, South of Iran. *Hepat Mon* 2015; **15**: e29219 [PMID: 26834784 DOI: 10.5812/hepatmon.29219]

114 **Ehteram H**, Ramezani A, Eslamifar A, Sofian M, Banifazl M, Ghassemi S, Aghakhani A, Mashayekhi P. Seroprevalence of Hepatitis E Virus infection among volunteer blood donors in central province of Iran in 2012. *Iran J Microbiol* 2013; **5**: 172-176 [PMID: 23825737]

115 **Taremi M**, Gachkar L, MahmoudArabi S, Kheradpezhouh M, Khoshbaten M. Prevalence of antibodies to hepatitis E virus among male blood donors in Tabriz, Islamic Republic of Iran. *East Mediterr Health J* 2007; **13**: 98-102 [PMID: 17546911]

116 **Takeda H**, Matsubayashi K, Sakata H, Sato S, Kato T, Hino S, Tadokoro K, Ikeda H. A nationwide survey for prevalence of hepatitis E virus antibody in qualified blood donors in Japan. *Vox Sang* 2010; **99**: 307-313 [PMID: 20576022 DOI: 10.1111/j.1423-0410.2010.01362.x]

117 **Shrestha AC**, Flower RL, Seed CR, Rajkarnikar M, Shrestha SK, Thapa U, Hoad VC, Faddy HM. Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in Nepal. *BMC Infect Dis* 2016; **16**: 707 [PMID: 27887586 DOI: 10.1186/s12879-016-2043-8]

118 **Nasrallah GK**, Al Absi ES, Ghandour R, Ali NH, Taleb S, Hedaya L, Ali F, Huwaidy M, Husseini A. Seroprevalence of hepatitis E virus among blood donors in Qatar (2013-2016). *Transfusion* 2017; **57**: 1801-1807 [PMID: 28453178 DOI: 10.1111/trf.14116]

119 **Jupattanasin S**, Chainuvati S, Chotiyaputta W, Chanmanee T, Supapueng O, Charoonruangrit U, Oota S, Louisirirotchanakul S. A Nationwide Survey of the Seroprevalence of Hepatitis E Virus Infections Among Blood Donors in Thailand. *Viral Immunol* 2019; **32**: 302-307 [PMID: 31403386 DOI: 10.1089/vim.2018.0146]

120 **Traoré KA**, Ouoba JB, Rouamba H, Nébié YK, Dahourou H, Rossetto F, Traoré AS, Barro N, Roques P. Hepatitis E Virus Prevalence among Blood Donors, Ouagadougou, Burkina Faso. *Emerg Infect Dis* 2016; **22**: 755-757 [PMID: 26982195 DOI: 10.3201/eid2204.151728]

121 **Ibrahim EH**, Abdelwahab SF, Nady S, Hashem M, Galal G, Sobhy M, Saleh AS, Shata MT. Prevalence of anti-HEV IgM among blood donors in Egypt. *Egypt J Immunol* 2011; **18**: 47-58 [PMID: 23082470]

122 **Meldal BH**, Sarkodie F, Owusu-Ofori S, Allain JP. Hepatitis E virus infection in Ghanaian blood donors - the importance of immunoassay selection and confirmation. *Vox Sang* 2013; **104**: 30-36 [PMID: 22845878 DOI: 10.1111/j.1423-0410.2012.01637.x]

123 **Lopes T**, Cable R, Pistorius C, Maponga T, Ijaz S, Preiser W, Tedder R, Andersson MI. Racial differences in seroprevalence of HAV and HEV in blood donors in the Western Cape, South Africa: a clue to the predominant HEV genotype? *Epidemiol Infect* 2017; **145**: 1910-1912 [PMID: 28357965 DOI: 10.1017/S0950268817000565]

124 **Ben-Ayed Y**, Hannachi H, Ben-Alaya-Bouafif N, Gouider E, Triki H, Bahri O. Hepatitis E virus seroprevalence among hemodialysis and hemophiliac patients in Tunisia (North Africa). *J Med Virol* 2015; **87**: 441-445 [PMID: 25331682 DOI: 10.1002/jmv.24082]

125 **Schemmerer M**, Rauh C, Jilg W, Wenzel JJ. Time course of hepatitis E-specific antibodies in adults. *J Viral Hepat* 2017; **24**: 75-79 [PMID: 27699946 DOI: 10.1111/jvh.12621]

126 **Takahashi M**, Tanaka T, Takahashi H, Hoshino Y, Nagashima S, Jirintai, Mizuo H, Yazaki Y, Takagi T, Azuma M, Kusano E, Isoda N, Sugano K, Okamoto H. Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. *J Clin Microbiol* 2010; **48**: 1112-1125 [PMID: 20107086 DOI: 10.1128/JCM.02002-09]

127 **Goel A**, Vijay HJ, Katiyar H, Aggarwal R. Prevalence of hepatitis E viraemia among blood donors: a systematic review. *Vox Sang* 2020; **115**: 120-132 [PMID: 32030767 DOI: 10.1111/vox.12887]

128 **Tedder RS**, Tettmar KI, Brailsford SR, Said B, Ushiro-Lumb I, Kitchen A, Morgan D, Lattimore S, Tossell J, Ijaz S, Hewitt PE. Virology, serology, and demography of hepatitis E viremic blood donors in South East England. *Transfusion* 2016; **56**: 1529-1536 [PMID: 26841005 DOI: 10.1111/trf.13498]

129 **Riveiro-Barciela M**, Rando-Segura A, Barreira-Díaz A, Bes M, P Ruzo S, Piron M, Quer J, Sauleda S, Rodríguez-Frías F, Esteban R, Buti M. Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis? *J Viral Hepat* 2020; **27**: 747-753 [PMID: 32106351 DOI: 10.1111/jvh.13285]

130 **Kar P,** Karna R. A Review of the Diagnosis and Management of Hepatitis E. Curr Treat Options *Infect Dis* 2020: 1-11 [DOI: 10.1007/s40506-020-00235-4]

131 **Hartl J**, Otto B, Madden RG, Webb G, Woolson KL, Kriston L, Vettorazzi E, Lohse AW, Dalton HR, Pischke S. Hepatitis E Seroprevalence in Europe: A Meta-Analysis. *Viruses* 2016; **8** [PMID: 27509518 DOI: 10.3390/v8080211]

132 **Shrestha AC**, Flower RL, Seed CR, Stramer SL, Faddy HM. A Comparative Study of Assay Performance of Commercial Hepatitis E Virus Enzyme-Linked Immunosorbent Assay Kits in Australian Blood Donor Samples. *J Blood Transfus* 2016; **2016**: 9647675 [PMID: 27891290 DOI: 10.1155/2016/9647675]

133 **Galli C**, Fomiatti L, Tagliacarne C, Velati C, Zanetti AR, Castaldi S, Romanò L. Seroprevalence of hepatitis E virus among blood donors in northern Italy (Sondrio, Lombardy) determined by three different assays. *Blood Transfus* 2017; **15**: 502-505 [PMID: 29059041 DOI: 10.2450/2017.0089-17]

134 **Park HK**, Jeong SH, Kim JW, Woo BH, Lee DH, Kim HY, Ahn S. Seroprevalence of anti-hepatitis E virus (HEV) in a Korean population: comparison of two commercial anti-HEV assays. *BMC Infect Dis* 2012; **12**: 142 [PMID: 22726615 DOI: 10.1186/1471-2334-12-142]

135 **Bendall R**, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. *J Med Virol* 2010; **82**: 799-805 [PMID: 20336757 DOI: 10.1002/jmv.21656]

136 **Matsubayashi K**, Nagaoka Y, Sakata H, Sato S, Fukai K, Kato T, Takahashi K, Mishiro S, Imai M, Takeda N, Ikeda H. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. *Transfusion* 2004; **44**: 934-940 [PMID: 15157263 DOI: 10.1111/j.1537-2995.2004.03300.x]

137 **Okano H**, Nakano T, Ito R, Tanaka A, Hoshi Y, Matsubayashi K, Asakawa H, Nose K, Tsuruga S, Tochio T, Kumazawa H, Isono Y, Tanaka H, Matsusaki S, Sase T, Saito T, Mukai K, Nishimura A, Kawakami K, Nagashima S, Takahashi M, Okamoto H. The spontaneous clearance of hepatitis E virus (HEV) and emergence of HEV antibodies in a transfusion-transmitted chronic hepatitis E case after completion of chemotherapy for acute myeloid leukemia. *Clin J Gastroenterol* 2020; **13**: 252-259 [PMID: 31342463 DOI: 10.1007/s12328-019-01024-3]

138 **Gallian P**, Pouchol E, Djoudi R, Lhomme S, Mouna L, Gross S, Bierling P, Assal A, Kamar N, Mallet V, Roque-Afonso AM, Izopet J, Tiberghien P. Transfusion-Transmitted Hepatitis E Virus Infection in France. *Transfus Med Rev* 2019; **33**: 146-153 [PMID: 31327668 DOI: 10.1016/j.tmrv.2019.06.001]

139 **Ledesma J**, Williams D, Stanford FA, Hewitt PE, Zuckerman M, Bansal S, Dhawan A, Mbisa JL, Tedder R, Ijaz S. Resolution by deep sequencing of a dual hepatitis E virus infection transmitted via blood components. *J Gen Virol* 2019; **100**: 1491-1500 [PMID: 31592753 DOI: 10.1099/jgv.0.001302]

140 **Satake M**, Matsubayashi K, Hoshi Y, Taira R, Furui Y, Kokudo N, Akamatsu N, Yoshizumi T, Ohkohchi N, Okamoto H, Miyoshi M, Tamura A, Fuse K, Tadokoro K. Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression. *Transfusion* 2017; **57**: 280-288 [PMID: 28144952 DOI: 10.1111/trf.13994]

141 **Lhomme S**, Bardiaux L, Abravanel F, Gallian P, Kamar N, Izopet J. Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France. *Emerg Infect Dis* 2017; **23**: 353-356 [PMID: 28098552 DOI: 10.3201/eid2302.161094]

142 **Yamazaki Y**, Naganuma A, Arai Y, Takeuchi S, Kobayashi T, Takakusagi S, Hatanaka T, Hoshino T, Namikawa M, Hashizume H, Takizawa D, Ohyama T, Suzuki H, Horiguchi N, Takagi H, Sato K, Kakizaki S, Kusano M, Nagashima S, Takahashi M, Okamoto H, Yamada M. Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015. *Hepatol Res* 2017; **47**: 435-445 [PMID: 27322051 DOI: 10.1111/hepr.12765]

143 **Belliere J**, Abravanel F, Nogier MB, Martinez S, Cintas P, Lhomme S, Lavayssière L, Cointault O, Faguer S, Izopet J, Kamar N. Transfusion-acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient. *Transpl Infect Dis* 2017; **19** [PMID: 28963742 DOI: 10.1111/tid.12784]

144 **Riveiro-Barciela M**, Sauleda S, Quer J, Salvador F, Gregori J, Pirón M, Rodríguez-Frías F, Buti M. Red blood cell transfusion-transmitted acute hepatitis E in an immunocompetent subject in Europe: a case report. *Transfusion* 2017; **57**: 244-247 [PMID: 27785789 DOI: 10.1111/trf.13876]

145 **Hoad VC**, Gibbs T, Ravikumara M, Nash M, Levy A, Tracy SL, Mews C, Perkowska-Guse Z, Faddy HM, Bowden S. First confirmed case of transfusion-transmitted hepatitis E in Australia. *Med J Aust* 2017; **206**: 289-290 [PMID: 28403756 DOI: 10.5694/mja16.01090]

146 **Matsui T**, Kang JH, Matsubayashi K, Yamazaki H, Nagai K, Sakata H, Tsuji K, Maguchi H. Rare case of transfusion-transmitted hepatitis E from the blood of a donor infected with the hepatitis E virus genotype 3 indigenous to Japan: Viral dynamics from onset to recovery. *Hepatol Res* 2015; **45**: 698-704 [PMID: 25041213 DOI: 10.1111/hepr.12390]

147 **Huzly D**, Umhau M, Bettinger D, Cathomen T, Emmerich F, Hasselblatt P, Hengel H, Herzog R, Kappert O, Maassen S, Schorb E, Schulz-Huotari C, Thimme R, Unmüssig R, Wenzel JJ, Panning M. Transfusion-transmitted hepatitis E in Germany, 2013. *Euro Surveill* 2014; **19** [PMID: 24906377 DOI: 10.2807/1560-7917.es2014.19.21.20812]

148 **Coilly A**, Haïm-Boukobza S, Roche B, Antonini TM, Pause A, Mokhtari C, Becq A, Farahmand H, Hauser L, Duclos-Vallée JC, Samuel D, Adam R, Roque-Afonso AM. Posttransplantation hepatitis E: transfusion-transmitted hepatitis rising from the ashes. *Transplantation* 2013; **96**: e4-e6 [PMID: 23857003 DOI: 10.1097/TP.0b013e318296c9f7]

149 **Boxall E**, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S, Teo CG. Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. *Transfus Med* 2006; **16**: 79-83 [PMID: 16623913 DOI: 10.1111/j.1365-3148.2006.00652.x]

150 **Mitsui T**, Tsukamoto Y, Yamazaki C, Masuko K, Tsuda F, Takahashi M, Nishizawa T, Okamoto H. Prevalence of hepatitis E virus infection among hemodialysis patients in Japan: evidence for infection with a genotype 3 HEV by blood transfusion. *J Med Virol* 2004; **74**: 563-572 [PMID: 15484278 DOI: 10.1002/jmv.20215]

151 **Ticehurst JR**, Pisanic N, Forman MS, Ordak C, Heaney CD, Ong E, Linnen JM, Ness PM, Guo N, Shan H, Nelson KE. Probable transmission of hepatitis E virus (HEV) via transfusion in the United States. *Transfusion* 2019; **59**: 1024-1034 [PMID: 30702157 DOI: 10.1111/trf.15140]

152 **Andonov A**, Rock G, Lin L, Borlang J, Hooper J, Grudeski E, Wu J; Members of the Canadian Apheresis Group (CAG). Serological and molecular evidence of a plausible transmission of hepatitis E virus through pooled plasma. *Vox Sang* 2014; **107**: 213-219 [PMID: 24830322 DOI: 10.1111/vox.12156]

153 **Mrzljak A**, Dinjar-Kujundzic P, Knotek M, Kudumija B, Ilic M, Gulin M, Zibar L, Hrstic I, Jurekovic Z, Kolaric B, Jemersic L, Prpic J, Tomljenovic M, Vilibic-Cavlek T. Seroepidemiology of hepatitis E in patients on haemodialysis in Croatia. *Int Urol Nephrol* 2020; **52**: 371-378 [PMID: 31894559 DOI: 10.1007/s11255-019-02363-3]

154 **Slavov SN**, Maçonetto JDM, Martinez EZ, Silva-Pinto AC, Covas DT, Eis-Hübinger AM, Kashima S. Prevalence of hepatitis E virus infection in multiple transfused Brazilian patients with thalassemia and sickle cell disease. *J Med Virol* 2019; **91**: 1693-1697 [PMID: 31066064 DOI: 10.1002/jmv.25498]

155 **Dalvand N**, Dalvand A, Sharifi Z, Hosseini SM. Prevalence of hepatitis E virus in thalassemia patients with hepatitis C in Tehran, Iran. *Iran J Microbiol* 2019; **11**: 535-540 [PMID: 32148686]

156 **Ankcorn MJ**, Fox TA, Ijaz S, Nicholas C, Houston E, Longair I, Suri D, Mattes FM, Walker JL, Tedder RS, Sekhar M. Characterising the risk of Hepatitis E virus infection in haematological malignancies: a UK prospective prevalence study. *Br J Haematol* 2019; **186**: 191-195 [PMID: 30768677 DOI: 10.1111/bjh.15796]

157 **Haïm-Boukobza S**, Ferey MP, Vétillard AL, Jeblaoui A, Pélissier E, Pelletier G, Teillet L, Roque-Afonso AM. Transfusion-transmitted hepatitis E in a misleading context of autoimmunity and drug-induced toxicity. *J Hepatol* 2012; **57**: 1374-1378 [PMID: 22885386 DOI: 10.1016/j.jhep.2012.08.001]

158 **Loyrion E**, Trouve-Buisson T, Pouzol P, Larrat S, Decaens T, Payen JF. Hepatitis E Virus Infection after Platelet Transfusion in an Immunocompetent Trauma Patient. *Emerg Infect Dis* 2017; **23**: 146-147 [PMID: 27983485 DOI: 10.3201/eid2301.160923]

159 **Peters van Ton AM**, Gevers TJ, Drenth JP. Antiviral therapy in chronic hepatitis E: a systematic review. *J Viral Hepat* 2015; **22**: 965-973 [PMID: 25760481 DOI: 10.1111/jvh.12403]

160 **Kamar N**, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, Cannesson A, Cassuto-Viguier E, Thervet E, Conti F, Lebray P, Dalton HR, Santella R, Kanaan N, Essig M, Mousson C, Radenne S, Roque-Afonso AM, Izopet J, Rostaing L. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. *Gastroenterology* 2011; **140**: 1481-1489 [PMID: 21354150 DOI: 10.1053/j.gastro.2011.02.050]

161 **Pas SD**, de Man RA, Mulders C, Balk AH, van Hal PT, Weimar W, Koopmans MP, Osterhaus AD, van der Eijk AA. Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. *Emerg Infect Dis* 2012; **18**: 869-872 [PMID: 22516170 DOI: 10.3201/eid1805.111712]

162 **Kamar N**, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, Cointault O, Esposito L, Abravanel F, Danjoux M, Durand D, Vinel JP, Izopet J, Rostaing L. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. *N Engl J Med* 2008; **358**: 811-817 [PMID: 18287603 DOI: 10.1056/NEJMoa0706992]

163 **Haagsma EB**, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, Koopmans MP. Chronic hepatitis E virus infection in liver transplant recipients. *Liver Transpl* 2008; **14**: 547-553 [PMID: 18383084 DOI: 10.1002/lt.21480]

164 **von Felden J**, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani MT, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse AW, Cornelissen JJ, de Man RA, Mallet V. The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. *J Hepatol* 2019; **71**: 465-472 [PMID: 31108159 DOI: 10.1016/j.jhep.2019.04.022]

165 **Cao D**, Cao QM, Subramaniam S, Yugo DM, Heffron CL, Rogers AJ, Kenney SP, Tian D, Matzinger SR, Overend C, Catanzaro N, LeRoith T, Wang H, Piñeyro P, Lindstrom N, Clark-Deener S, Yuan L, Meng XJ. Pig model mimicking chronic hepatitis E virus infection in immunocompromised patients to assess immune correlates during chronicity. *Proc Natl Acad Sci U S A* 2017; **114**: 6914-6923 [PMID: 28630341 DOI: 10.1073/pnas.1705446114]

166 **Saravanabalaji S**, Tripathy AS, Dhoot RR, Chadha MS, Kakrani AL, Arankalle VA. Viral load, antibody titers and recombinant open reading frame 2 protein-induced TH1/TH2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis e. *Intervirology* 2009; **52**: 78-85 [PMID: 19401616 DOI: 10.1159/000214862]

167 **Péron JM**, Abravanel F, Guillaume M, Gérolami R, Nana J, Anty R, Pariente A, Renou C, Bureau C, Robic MA, Alric L, Vinel JP, Izopet J, Kamar N. Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. *Liver Int* 2016; **36**: 328-333 [PMID: 26179015 DOI: 10.1111/liv.12911]

168 **McPherson S**, Elsharkawy AM, Ankcorn M, Ijaz S, Powell J, Rowe I, Tedder R, Andrews PA. Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation. *Transplantation* 2018; **102**: 15-20 [PMID: 28795981 DOI: 10.1097/TP.0000000000001908]

169 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. *J Hepatol* 2018; **68**: 1256-1271 [DOI: 10.1016/j.jhep.2012.09.013]

170 **Wang Y**, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, Janssen HL, Metselaar HJ, Peppelenbosch MP, Pan Q. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. *Gastroenterology* 2014; **146**: 1775-1783 [PMID: 24582714 DOI: 10.1053/j.gastro.2014.02.036]

171 **Kamar N**, Lhomme S, Abravanel F, Marion O, Peron JM, Alric L, Izopet J. Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis. *Viruses* 2016; **8** [PMID: 27537905 DOI: 10.3390/v8080222]

172 **Gorris M**, van der Lecq BM, van Erpecum KJ, de Bruijne J. Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysis. *J Viral Hepat* 2021; **28**: 454-463 [PMID: 33301609 DOI: 10.1111/jvh.13456]

173 **De Winter BCM**, Hesselink DA, Kamar N. Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. *Pharmacol Res* 2018; **130**: 308-315 [PMID: 29499270 DOI: 10.1016/j.phrs.2018.02.030]

174 **Kamar N**, Lhomme S, Abravanel F, Cointault O, Esposito L, Cardeau-Desangles I, Del Bello A, Dörr G, Lavayssière L, Nogier MB, Guitard J, Ribes D, Goin AL, Broué P, Metsu D, Sauné K, Rostaing L, Izopet J. An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. *Transplantation* 2015; **99**: 2124-2131 [PMID: 26214817 DOI: 10.1097/TP.0000000000000850]

175 **Todt D**, Meister TL, Steinmann E. Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse. *Curr Opin Virol* 2018; **32**: 80-87 [PMID: 30384328 DOI: 10.1016/j.coviro.2018.10.001]

176 **Alric L**, Bonnet D, Laurent G, Kamar N, Izopet J. Chronic hepatitis E virus infection: successful virologic response to pegylated interferon-alpha therapy. *Ann Intern Med* 2010; **153**: 135-136 [PMID: 20547885 DOI: 10.7326/0003-4819-153-2-201007200-00256]

177 **Kamar N**, Abravanel F, Garrouste C, Cardeau-Desangles I, Mansuy JM, Weclawiak H, Izopet J, Rostaing L. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. *Nephrol Dial Transplant* 2010; **25**: 2792-2795 [PMID: 20494897 DOI: 10.1093/ndt/gfq282]

178 **Rivero-Juarez A**, Lopez-Lopez P, Frias M, Rivero A. Hepatitis E Infection in HIV-Infected Patients. *Front Microbiol* 2019; **10**: 1425 [PMID: 31297100 DOI: 10.3389/fmicb.2019.01425]

179 **Nakano R**, Ohira M, Ishiyama K, Ide K, Kobayashi T, Tahara H, Shimizu S, Arihiro K, Imamura M, Chayama K, Tanaka Y, Ohdan H. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report. *Transplant Proc* 2017; **49**: 1634-1638 [PMID: 28838454 DOI: 10.1016/j.transproceed.2017.05.006]

180 **Selzner N**, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. *J Hepatol* 2011; **55**: 207-217 [PMID: 21145865 DOI: 10.1016/j.jhep.2010.11.012]

181 **Kamar N**, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau-Desangles I, Mansuy JM, Selves J, Peron JM, Otal P, Muscari F, Izopet J. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. *Clin Infect Dis* 2010; **50**: e30-e33 [PMID: 20113176 DOI: 10.1086/650488]

182 **Haagsma EB**, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. *Liver Transpl* 2010; **16**: 474-477 [PMID: 20373458 DOI: 10.1002/lt.22014]

183 **Ollivier-Hourmand I**, Lebedel L, Lecouf A, Allaire M, Nguyen TTN, Lier C, Dao T. Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients. *BMC Infect Dis* 2020; **20**: 522 [PMID: 32677900 DOI: 10.1186/s12879-020-05212-2]

184 **Dao Thi VL**, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, Gouttenoire J. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. *Gastroenterology* 2016; **150**: 82-85.e4 [PMID: 26408347 DOI: 10.1053/j.gastro.2015.09.011]

185 **van der Valk M**, Zaaijer HL, Kater AP, Schinkel J. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. *J Hepatol* 2017; **66**: 242-243 [PMID: 27702641 DOI: 10.1016/j.jhep.2016.09.014]

186 **van Wezel EM,** de Bruijne J, Damman K, Bijmolen M, van den Berg AP, Verschuuren EAM, Ruigrok GA, Riezebos-Brilman A, Knoester M. Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response. *Open Forum Infect Di* 2019; 6 [DOI: 10.1093/ofid/ofz346]

187 **Cornberg M**, Pischke S, Müller T, Behrendt P, Piecha F, Benckert J, Todt D, Steinmann E, Papkalla A, von Karpowitz M, Koch A, Lohse A, Hardtke S, Manns MP, Wedemeyer H. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. *J Hepatol* 2020; **73**: 696-699 [PMID: 32624195 DOI: 10.1016/j.jhep.2020.05.020]

188 **Tedder RS**, Ijaz S, Kitchen A, Ushiro-Lumb I, Tettmar KI, Hewitt P, Andrews N. Hepatitis E risks: pigs or blood-that is the question. *Transfusion* 2017; **57**: 267-272 [PMID: 28194857 DOI: 10.1111/trf.13976]

189 **Denner J**. Hepatitis E virus (HEV)-The Future. *Viruses* 2019; **11** [PMID: 30871152 DOI: 10.3390/v11030251]

190 **Wu X**, Chen P, Lin H, Hao X, Liang Z. Hepatitis E virus: Current epidemiology and vaccine. *Hum Vaccin Immunother* 2016; **12**: 2603-2610 [PMID: 27184971 DOI: 10.1080/21645515.2016.1184806]

191 **Denner J**, Pischke S, Steinmann E, Blümel J, Glebe D. Why all blood donations should be tested for hepatitis E virus (HEV). *BMC Infect Dis* 2019; **19**: 541 [PMID: 31221098 DOI: 10.1186/s12879-019-4190-1]

192 **Domanović D**, Tedder R, Blümel J, Zaaijer H, Gallian P, Niederhauser C, Sauleda Oliveras S, O'Riordan J, Boland F, Harritshøj L, Nascimento MSJ, Ciccaglione AR, Politis C, Adlhoch C, Flan B, Oualikene-Gonin W, Rautmann G, Strengers P, Hewitt P. Hepatitis E and blood donation safety in selected European countries: a shift to screening? *Euro Surveill* 2017; **22** [PMID: 28449730 DOI: 10.2807/1560-7917.ES.2017.22.16.30514]

193 **Matsubayashi K,** Sakata H, Ikeda H. Hepatitis E virus infection and blood transfusion in Japan. *ISBT Sci Ser* 2011; **6**: 344-349 [DOI: 10.1111/j.1751-2824.2011.01512.x]

194 **Lee CK**, Chau TN, Lim W, Tsoi WC, Lai ST, Lin CK. Prevention of transfusion-transmitted hepatitis E by donor-initiated self exclusion. *Transfus Med* 2005; **15**: 133-135 [PMID: 15859980 DOI: 10.1111/j.0958-7578.2005.00563.x]

195 **Pawlotsky JM**. Hepatitis E screening for blood donations: an urgent need? *Lancet* 2014; **384**: 1729-1730 [PMID: 25078305 DOI: 10.1016/S0140-6736(14)61187-9]

196 **Boland F**, Martinez A, Pomeroy L, O'Flaherty N. Blood Donor Screening for Hepatitis E Virus in the European Union. *Transfus Med Hemother* 2019; **46**: 95-103 [PMID: 31191195 DOI: 10.1159/000499121]

197 American Association of Blood Banks. (2014) Hepatitis E virus [cited 20 March 2021]. Available from: https://www.aabb.org/docs/default-source/default-document-library/regulatory/eid/hepatitis-e-virus.pdf?sfvrsn=9f532d0e\_2

198 **Kamp C**, Blümel J, Baylis SA, Bekeredjian-Ding I, Chudy M, Heiden M, Henseler O, Keller-Stanislawski B, de Vos AS, Funk MB. Impact of hepatitis E virus testing on the safety of blood components in Germany - results of a simulation study. *Vox Sang* 2018; **113**: 811-813 [PMID: 30318777 DOI: 10.1111/vox.12719]

199 **Bi H**, Yang R, Wu C, Xia J. Hepatitis E virus and blood transfusion safety. *Epidemiol Infect* 2020; **148**: e158 [PMID: 32594963 DOI: 10.1017/S0950268820001429]

200 **Pischke S**, Peron JM, von Wulffen M, von Felden J, Höner Zu Siederdissen C, Fournier S, Lütgehetmann M, Iking-Konert C, Bettinger D, Par G, Thimme R, Cantagrel A, Lohse AW, Wedemeyer H, de Man R, Mallet V. Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. *Viruses* 2019; **11** [PMID: 30813268 DOI: 10.3390/v11020186]

201 **Bauer H**, Luxembourger C, Gottenberg JE, Fournier S, Abravanel F, Cantagrel A, Chatelus E, Claudepierre P, Hudry C, Izopet J, Fabre S, Lefevre G, Marguerie L, Martin A, Messer L, Molto A, Pallot-Prades B, Pers YM, Roque-Afonso AM, Roux C, Sordet C, Soubrier M, Veissier C, Wendling D, Péron JM, Sibilia J; Club Rhumatismes et Inflammation, a section of the French Society of Rheumatology. Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study. *Medicine (Baltimore)* 2015; **94**: e675 [PMID: 25860212 DOI: 10.1097/MD.0000000000000675]

202 **Kenfak-Foguena A**, Schöni-Affolter F, Bürgisser P, Witteck A, Darling KE, Kovari H, Kaiser L, Evison JM, Elzi L, Gurter-De La Fuente V, Jost J, Moradpour D, Abravanel F, Izpopet J, Cavassini M; Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland. Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. *Emerg Infect Dis* 2011; **17**: 1074-1078 [PMID: 21749774 DOI: 10.3201/eid/1706.101067]

203 **Buescher G**, Ozga AK, Lorenz E, Pischke S, May J, Addo MM, Horvatits T. Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis. *Liver Int* 2021; **41**: 449-455 [PMID: 33034121 DOI: 10.1111/liv.14695]

204 **Navaneethan U**, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: understanding the pathogenesis. *Liver Int* 2008; **28**: 1190-1199 [PMID: 18662274 DOI: 10.1111/j.1478-3231.2008.01840.x]

205 **Anty R**, Ollier L, Péron JM, Nicand E, Cannavo I, Bongain A, Giordanengo V, Tran A. First case report of an acute genotype 3 hepatitis E infected pregnant woman living in South-Eastern France. *J Clin Virol* 2012; **54**: 76-78 [PMID: 22336086 DOI: 10.1016/j.jcv.2012.01.016]

206 **Tabatabai J**, Wenzel JJ, Soboletzki M, Flux C, Navid MH, Schnitzler P. First case report of an acute hepatitis E subgenotype 3c infection during pregnancy in Germany. *J Clin Virol* 2014; **61**: 170-172 [PMID: 24996764 DOI: 10.1016/j.jcv.2014.06.008]

207 **Bouthry E**, Benachi A, Vivanti AJ, Letamendia E, Vauloup-Fellous C, Roque-Afonso AM. Autochthonous Hepatitis E during Pregnancy, France. *Emerg Infect Dis* 2018; **24**: 1586-1587 [PMID: 30016249 DOI: 10.3201/eid2408.180105]

208 **Jilani N**, Das BC, Husain SA, Baweja UK, Chattopadhya D, Gupta RK, Sardana S, Kar P. Hepatitis E virus infection and fulminant hepatic failure during pregnancy. *J Gastroenterol Hepatol* 2007; **22**: 676-682 [PMID: 17444855 DOI: 10.1111/j.1440-1746.2007.04913.x]

209 **Kar P**, Jilani N, Husain SA, Pasha ST, Anand R, Rai A, Das BC. Does hepatitis E viral load and genotypes influence the final outcome of acute liver failure during pregnancy? *Am J Gastroenterol* 2008; **103**: 2495-2501 [PMID: 18785952 DOI: 10.1111/j.1572-0241.2008.02032.x]

210 **Kar P**, Sengupta A. A guide to the management of hepatitis E infection during pregnancy. *Expert Rev Gastroenterol Hepatol* 2019; **13**: 205-211 [PMID: 30791760 DOI: 10.1080/17474124.2019.1568869]

211 **Horvatits T**, Westhölter D, Peine S, Schulze Zur Wiesch J, Lohse AW, Lütgehetmann M, Pischke S. Lack of evidence for human serum albumin as major source of HEV infections. *Transfus Med* 2018; **28**: 470-471 [PMID: 29707836 DOI: 10.1111/tme.12536]

212 **Juhl D**, Nowak-Göttl U, Blümel J, Görg S, Hennig H. Lack of evidence for the transmission of hepatitis E virus by coagulation factor concentrates based on seroprevalence data. *Transfus Med* 2018; **28**: 427-432 [PMID: 29280212 DOI: 10.1111/tme.12498]

213 **de Vos AS**, Janssen MP, Zaaijer HL, Hogema BM. Cost-effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands. *Transfusion* 2017; **57**: 258-266 [PMID: 28144956 DOI: 10.1111/trf.13978]

214 **Gallian P**, Lhomme S, Morel P, Gross S, Mantovani C, Hauser L, Tinard X, Pouchol E, Djoudi R, Assal A, Abravanel F, Izopet J, Tiberghien P. Risk for Hepatitis E Virus Transmission by Solvent/Detergent-Treated Plasma. *Emerg Infect Dis* 2020; **26**: 2881-2886 [PMID: 33219652 DOI: 10.3201/eid2612.191482]

215 **Hauser L**, Roque-Afonso AM, Beylouné A, Simonet M, Deau Fischer B, Burin des Roziers N, Mallet V, Tiberghien P, Bierling P. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. *Blood* 2014; **123**: 796-797 [PMID: 24482503 DOI: 10.1182/blood-2013-09-524348]

216 **Farcet MR**, Lackner C, Antoine G, Rabel PO, Wieser A, Flicker A, Unger U, Modrof J, Kreil TR. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes. *Transfusion* 2016; **56**: 383-391 [PMID: 26399175 DOI: 10.1111/trf.13343]

217 **Kapsch AM**, Farcet MR, Wieser A, Ahmad MQ, Miyabayashi T, Baylis SA, Blümel J, Kreil TR. Antibody-enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin. *Transfusion* 2020; **60**: 2500-2507 [PMID: 32794187 DOI: 10.1111/trf.16014]

218 **Praditya D**, Friesland M, Gravemann U, Handke W, Todt D, Behrendt P, Müller TH, Steinmann E, Seltsam A. Hepatitis E virus is effectively inactivated in platelet concentrates by ultraviolet C light. *Vox Sang* 2020; **115**: 555-561 [PMID: 32383163 DOI: 10.1111/vox.12936]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflict of interest

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 10, 2021

**First decision:** June 24, 2021

**Article in press:**

**Specialty type:** Gastroenterology and Hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Anand AC, Kulkarni AV **S-Editor:** Chang KL **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**



**Figure 1 Recommended algorithm for management of transfusion-transmitted hepatitis E.**

**Table 1 Extrahepatic manifestations associated with hepatitis E virus infection**

|  |  |
| --- | --- |
| **System** | **Extrahepatic manifestations**  |
| Neurological | Guillain-Barré syndrome (GBS) |
|  | Neuralgic amyotrophy |
|  | Neuropathy |
|  | Bell’s palsy |
|  | Encephalitis |
|  | Transverse myelitis |
|  | Myositis |
|  | Myasthenia gravis |
|  | Pseudotumor cerebri |
|  | Seizure |
| Renal | Decrease glomerular filtration rate |
|  | Glomerulonephritis |
|  | Nephrotic syndrome  |
|  | Mixed cryoglobulinemia |
| Hematological | Thrombocytopenia |
|  | Hemolytic anemia |
|  | Aplastic anemia |
|  | Hemophagocytic syndrome |
|  | Monoclonal gammopathy of uncertain significance (MGUS) |
| Others | Thyroiditis |
|  | Pancreatitis |
|  | Myocarditis |
|  | Polyarthritis |

**Table 2 Hepatitis E virus ribonucleic acid prevalence in donor, only studies include more than 1000 study subjects are included**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Initial screening method** | **Number of donations screened** | **Number positive donations** | **Prevalence (95% CI)** | **HEV genotype: *n*/*N*** | **Median (range) viral load, IU/mL** | **Outcome of recipient**  |
| Europe |
| Fischer *et al*[45], 2015 | Austria | RT-PCR (plasma pool of 96 samples) with 95% LOD 11.6 IU/mL | 58915 | 7 | 0.012% | 3: 7/7 | (2,200 to 290000) | N/A |
| Vercouter *et al*[46], 2019 | Belgium | RT-PCR (plasma pool of 6 samples) with 95% LOD 18.6 IU/mL | 38137 | 7 | 0.018% | N/A | (153 to 8710) | N/A |
| Harritshøj *et al*[47], 2016 | Denmark | TMA assay on individual plasma with 95% LOD 7.9 IU/mL | 25637 | 11 | 0.043% (0.02% - 0.07%) | 3 (in 2 samples) | 13 (unquantifiable to 920) | (1) Look-back testing was performed in 7 recipients; all were tested negative for HEV RNA and anti-HEV IgM; (2) No recipient developed transaminitis; and (3) One patient had strongly positive anti-HEV IgG assay which may indicate recent HEV infection or secondary immune response by HEV re-exposure. |
| Gallian *et al*[48], 2014 | France | RT-PCR (plasma pool of 96 samples) with 95% LOD 23 IU/mL | 53234 | 22 | 0.045% (0.043%-0.047%). | 3c: 5/14; 3f: 8/14; 3 1/14 | (468 to 5155800) | N/A |
| Westhölter *et al*[49], 2018 | Germany | RT-PCR (plasma pool of 24 samples) with 95% LOD 18.6 IU/mL | 18737 | 23 | 0.123% | 3: 6/7 | (120 to 11200000) | (1) Retrospective analysis of 4 viremic donors showed that they were HEV-positive in previous donations; (2) In 3 donors, testing of the previously donated blood in pools of 24 samples failed to identify viremic donations but were tpositive in unpooled samples; (3) Fourteen recipients had received HEV RNA positive blood products; (4) One immunosuppressed recipient tested positive for HEV RNA, developed acute on chronic liver failure, and died; and (5) One immunocompetent recipient developed acute self-limited episode of hepatitis E |
| Dreier *et al*[50], 2018 | Germany | RT-PCR with 95% LOD 4.7 IU/ml for FFP, platelet concentrates, and RBC supernatant; 95% LOD 8.9 IU/mL for RBCs. | 235524 | 182 | 0.077% | 3: 4/4 | (< 25 to 69.4) | (1) Nine viremic donations were transfused to 6 different recipients; (2) Two recipients were immunocompromised (heart transplantation and leukemia); (3) Two recipients died shortly after transfusion for reasons other than HEV infection; and (4) None of the other 4 recipients developed acute HEV infection or had detectable HEV RNA / anti-HEV IgG |
| Corman *et al*[51], 2013 | Germany | RT-PCR (plasma pool of 96 samples mixed in metapools of 20) | 93955 | 14 | 0.015% | 3: 14/14 | (3.1 to 4.8 Log10 IU/mL) | N/A |
| Vollmer *et al*[52], 2012 | Germany | RT-PCR (plasma pool of 48 samples) with 95% LOD 4.7 IU/ml | 16125 | 13 | 0.081% | 3: 13/13 | (13 to 68100) | N/A |
| Baylis *et al*[53], 2012 | Germany | RT-PCR (plasma pool of 96 samples) with 95% LOD 250 IU/mL | 18,100 | 4 | 0.022% | 3 | (3.26 to 5.35 log10 copies/mL) | Donations screened positive for HEV were excluded from pharmaceutical production |
| O'Riordan *et al*[54], 2016 | Ireland | TMA assay with 95% LOD 5.5 IU/mL | 24985 | 5 | 0.020% (0.0065%-0.0467%) | 3: 3/3 | (10 to 44550) | N/A |
| Spreafico *et al*[55], 2020 | Italy | TMA assay on individual plasma with 95% LOD 7.9 IU/mL | 9726 | 1 | 0.010% (0.00%-0.06%) | N/A | N/A | N/A |
| Spada *et al*[56], 2018  | Italy | RT-PCR, plasma pool and sensitivity varies according to anti-HEV IgG and IgM status | 10011 | 0 | N/A | N/A | N/A | N/A |
| Hogema *et al*[57], 2015 | Netherlands | RT-PCR (plasma pool of 96 samples) with 95% LOD 38.4 IU/mL with the EasyMag extraction method and 10.3 IU/mL using Qiagen extracts | 59474 | 41 | 0.069% | 3c: 15/17; 3f: 2/17 | N/A | N/A |
| Slot *et al*[58], 2013 | Netherlands | RT-PCR (plasma pool of 48 or 480 samples) with 95% LOD 25 IU/mL | 40176 | 13 | 0.032% | 3: 16/17 | (< 25 to 470000) | N/A |
| Grabarczyk *et al*[59], 2018 | Poland | TMA assay on individual plasma with 95% LOD 7.9 IU/mL | 12664 | 10 | 0.079% (0.043%-0.145%) | 3i: 2/3; 3c: 1/3 | (16 to 6586 in 4 patients with positive results in qPCR) | N/A |
| Rivero-Juarez *et al*[60], 2019 | Spain | RT-PCR (plasma pool of 8 samples) with sensitivity 670 IU/mL | 11313 | 4 | 0.035% (0.01%-0.09%) | 3: 4/4 | (10788 to 2000000) | (1) Five patients received transfusions from HEV-infected donors; and (2) None of them showed an increase in alanine aminotransferase levels after transfusion |
| Sauleda *et al*[61], 2015  | Spain | TMA assay on individual plasma with 95% LOD 7.9 IU/mL | 9998 | 3 | 0.030% (0.01%-0.09%) | 3f (in 1 sample) | (250 to 2755) | N/A |
| Baylis *et al*[53], 2012 | Sweden | RT-PCR (plasma pool of 96 samples) with 95% LOD 250 IU/mL | 95835 | 12 | 0.013% | 3  | (3.20 to 5.68 log10 copies/mL) | Donations screened positive for HEV were excluded from pharmaceutical production |
| Harvala *et al*[62], 2019  | United Kingdom | RT-PCR (plasma pool of 24 samples) with 95% LOD 18.6 IU/mL | 1838747 | 480 | 0.026% | 3c: 112/149; 3e: 21/1493f: 12/149; 3a: 1/149; 2 distantly related to 3h, and 1 clustered distantly with 3a | 883 (1 to 3230000) | N/A |
| Thom *et al*[63], 2018 | United Kingdom | RT-PCR (plasma pool of 24 samples) | 94302 | 38 | 0.040% | 3: 10/10 | N/A | N/A |
| Hewitt *et al*[64], 2014 | United Kingdom | RT-PCR (plasma pool of 24 samples) | 225000 | 79 | 0.035% | 3: 79/79 | 3900 (50 to 2.37 × 106) | (1) Forty-three patients who had received blood components from HEV-infected donors were followed up; (2) The overall transmission rate was 42% (18 of 43 exposed patients); (3) One recipient developed clinical hepatitis and 4 recipients developed asymptomatic transaminitis; and (4) Four heavily immunosuppressed patients had delayed (37-38 wk) seroconversion or no antibodies detected |
| Cleland *et al*[65], 2013  | United Kingdom | Nested PCR (plasma pool of 24 samples) with 95% LOD 201 IU/mL | 43560 | 3 | 0.0069% | 3: 3/3 | N/A | N/A  |
| North America |
| Delage *et al*[66], 2019 | United States | RT-PCR on individual samples with 95% LOD 18.6 IU/mL | 50724 | 3 | 0.0059% | 3: 2/3; genotyping was unsuccessful in 1 patient | (23 to 1420) | N/A |
| Canada | 50765 | 11 | 0.022% | 3 (in 1 sample) |  (< 10 to 3080) |
| Roth *et al*[67], 2017 | United States | RT-PCR (plasma pool of 96 samples) with 95% LOD 18.6 IU/mL | 128021 | 4 | 0.003% | 3a: 3/3 | (3.0 to 3.8 log IU/mL) | N/A |
| Stramer *et al*[68], 2016 | United States | TMA assay on individual plasma with 95% LOD 7.9 IU/mL | 18829 | 2 | 0.011% (0.0018%-0.351%) | N/A | 14 IU/mL in one sample | N/A |
| Xu *et al*[69], 2013 | United States | RT-PCR (plasma pool of 7 to 8 samples) with 95% LOD 400 IU/mL and nested PCR with 95% LOD 200 IU/mL | 1939 | 0 | N/A | N/A | N/A | N/A |
| Baylis *et al*[53], 2012 | United States | RT-PCR (plasma pool of 96 samples) with 95% LOD 250 IU/mL | 51075 | 0 | N/A | N/A | N/A | N/A |
| Asia |
| Wen *et al*[70], 2018  | China | RT-PCR on individual plasma | 5345 | 15 | 0.281% | One 4h, another one clustered between genotype 2 and 4i | N/A | N/A |
| Tsoi *et al*[71], 2019  | Hong Kong | RT-PCR with 95% LOD 7.89 IU/mL | 10000 | 2 | 0.02% | 4 (in 1 sample) | N/A | N/A |
| Katiyar H *et al*[72], 2018  | India | RT-PCR (plasma pool of 3 samples) with LOD 100 IU/mL | 1799 | 0 | N/A | N/A | N/A | N/A |
| Minagi T *et al*[73], 2016  | Japan | RT-PCR (plasma pool of 50 or 500 samples) with 95% LOD 152 IU/mL | 620140 | 36 | 0.0058% | 3: 36/36 | (< 1.69 to 7.22 log10 copies/mL) | N/A |
| Intharasongkroh *et al*[74], 2019  | Thailand | RT-PCR (plasma pool of 6 samples) with 95% LOD 53.5 IU/mL | 30115 | 26 | 0.086% | 3: 6/6 | N/A | N/A |
| Others |
| Hoad *et al*[75], 2017 | Australia | TMA (plasma pool of 6 samples)  | 74131 | 1 | 0.0013% | N/A | 180 | N/A |
| Shrestha *et al*[76], 2016  | Australia | TMA assay on individual plasma with 95% LOD 7.9 IU/mL | 14799 | 1 | 0.0068% (0.0002%-0.0376% | 3 | 15000 | N/A |
| Hewitt *et al*[77], 2018 | New Zealand | RT-PCR (plasma pool of 8 to 12 samples) | 5000 | 0 | N/A | N/A | N/A | N/A |
| Maponga *et al*[78], 2020 | South Africa | TMA assay on individual plasma with 95% LOD 7.9IU/mL | 10000 | 1 | 0.01% | 3 | 79000 | All donations from donors with active HEV infection were discarded |

CI: Confidence interval; FFP: Fresh frozen plasma; HEV: Hepatitis E virus; Ig: Immunoglobulin; LOD: Limit of detection; RBC: Red blood cells; RNA: Ribonucleic acid; RT-PCR: Real time polymerase chain reaction; TMA: Transcription mediated amplification.

**Table 3 Seroprevalence of hepatitis E in blood donors**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Number of donations screened** | **Assay used** | **Number of samples positive for HEV IgG antibodies** | **Anti-HEV IgG prevalence (95% CI)** | **Number of samples positive for HEV IgM antibodies** | **Anti-HEV IgM prevalence (95% CI)** | **Number of samples positive for HEV RNA in anti-HEV IgM positive** | **Viral load, IU/mL** | **Genotype** |
| Europe |
| Fischer *et al*[45], 2015 | Austria | 1203 (from HEV RNA negative donors) | Wantai | 163 | 13.55% (11.6%-15.5%) | N/A | N/A | 0 | N/A | N/A |
| Vercouter *et al*[46], 2019 | Belgium | 356 (from HEV RNA negative donors) | Wantai | 31 | 8.71% (6.20%-12.10%) | 0 | N/A | 0 | N/A | N/A |
| Miletić *et al*[87], 2019 | Croatia | 1036 | 3 commercial ELISA assays were used, only findings with highest prevalence are shown | 209 | 20.17% | 46 | 4.44% | 0 | N/A | N/A |
| Holm *et al*[88], 2015 | Denmark | 504 | In-house NIH assay | 54 | 10.7% (8.2%-13.7%) | N/A | N/A | N/A | N/A | N/A |
| Wantai | 100 | 19.8% (16.4%-23.6%) |
| Dimeglio *et al*[89], 2018 | France | 300 | Wantai | 23 | 7.7% (4.9%-11.3%) | 2 | 0.6% (0.1%-2.4%) | 0 | N/A | N/A |
| Juhl *et al*[90], 2013 | Germany | 1019 | recomWell assay and Western blot | 69 | 6.8% (5.3%-8.3%) | N/A | N/A | N/A | N/A | N/A |
| Dalekos *et al*[91], 1998 | Greece | 3016 | Abbott assay and Western blot | 8 | 0.27% | 0 | N/A | N/A | N/A | N/A |
| O'Riordan *et al*[54], 2016 | Ireland | 1076 | Wantai | 57 | 5.3% (4.0%-6.8%) | 2 | 0.19% | 0 | N/A | N/A |
| Spreafico *et al*[55], 2020 | Italy | 767 | DiaPro | 52 | 6.8% (5.1%-8.8%) | 0 | N/A | 0 | N/A | N/A |
| Spada *et al*[56], 2018 | Italy | 10011 | Wantai | 869 | 8.7% (8.14%-9.25%) | 46 | 0.4% (0.34% - 0.61%) | 0 | N/A | N/A |
| De Sabato *et al*[92], 2017 | Italy | 170 | Bio-Chain Institute and Western blot | 15 | 8.82% | 3 | 1.76% | 0 | N/A | N/A |
| Lucarelli *et al*[93], 2016 | Italy | 313 | Wantai | 153 | 48.9% (43%-54%) | 2 | 0.6% (0.08%-2.3%) | 1 | 100 | 3 |
| Puttini *et al*[94], 2015 | Italy | 132 | EIAgen HEV IgG kit | 12 | 9.1% | N/A | N/A | N/A | N/A | N/A |
| Hogema *et al*[95], 2014 | Netherlands | 513 | Wantai | 58 | 11.31% | N/A | N/A | N/A | N/A | N/A |
| Slot *et al*[58], 2013 | Netherlands | 5239 | Wantai | 1401 | 26.7% (25.6%-28.0%) | 49 | 0.94% | 4 | Range: < 25 to 3700 | 3 |
| Grabarczyk *et al*[59], 2018 | Poland | 3079 | Wantai | 1340 | 43.52% (41.78%-45.28%) | 39 | 1.27% (0.93%-1.73%) | N/A | N/A | N/A |
| Sauleda *et al*[61], 2015 | Spain | 1082 | Wantai | 216 | 19.96% (17.60%-22.32%) | 13 | 1.20% | 0 | N/A | N/A |
| Mikrogen | 116 | 10.72% (8.90%-12.60%) |
| Mateos *et al*[96], 1999 | Spain | 863 | Abbott assay and Western blot | 34 | 3.9% | 0 | N/A | N/A | N/A | N/A |
| Niederhauser *et al*[97], 2018 | Switzerland | 3609 | Wantai | 737 | 20.4% (19.1%-21.8%) | N/A | N/A | N/A | N/A | N/A |
| Kaufmann *et al*[98], 2011 | Switzerland | 550 | MP Biomedicals | 27 | 4.9% | N/A | N/A | N/A | N/A | N/A |
| Thom *et al*[63], 2018 | United Kingdom | 1714 | Wantai | 104 | 6.1% (5.0%-7.3%) | N/A | N/A | N/A | N/A | N/A |
| Cleland *et al*[65], 2013 | United Kingdom | 1559 | Wantai | 73 | 4.7% (3.6%-5.8%) | 0 | N/A | N/A | N/A | N/A |
| Beale *et al*[99], 2011 | United Kingdom | 262 | Wantai | 31 | 11.8% | 4 | 1.5% | 0 | N/A | N/A |
| North America |
| Zafrullah *et al*[100], 2018 | United States | 5040 (from HEV RNA negative donor) | DSI | 569 | 11.29% | 146 | 2.90% | 0 | N/A | N/A |
| MP Biomedicals | 537 | 10.65% | 93 | 1.85% |
| Wantai | 619 | 12.28% | 34 | 0.67% |
| Stramer *et al*[68], 2016 | United States | 4499 | MP Biomedicals | 329 | 7.3% (6.6%-8.1%) | 26 | 0.58% (0.39%-0.85%) | N/A | N/A | N/A |
| Xu *et al*[69], 2013 | United States | 1939 | Wantai | 364 | 18.8% (17.0%-20.5%) | 8 | 0.4% (0.1%-0.7%) | 0 | N/A | N/A |
| South America |
| Di Lello *et al*[101], 2020 | Argentina | 391 | DiaPro | 44 | 11.3% | 8 | 2.0% | 0 | N/A | N/A |
| Bangueses *et al*[102], 2020 | Uruguay | 400 | DiaPro | 40 | 10% | 19 | 4.75% | 3 | N/A | 3 |
| Asia |  |  |  |  |  |  |  |  |  |  |
| Nouhin *et al*[103], 2016 | Cambodia | 301 | Wantai | 85 | 28.2% (23.4%-33.5%) | 3 | 1.0% (0.01%-1.8%) | 1 | 956 | 3 |
| Chen *et al*[104], 2019 | China | 4044 | Wantai | 799 | 19.8% (18.6%-21.0%) | 43 | 1.1% (0.8%-1.4%) | 2 | N/A | 4 |
| Wen *et al*[70], 2018 | China | 5345 | Wantai | 1227 | 22.96% | 38 | 0.71% | 15 | N/A | N/A |
| Wang *et al*[105], 2017 | China | 9069 | Wantai | 2682 | 29.57% | 131 | 1.44% | 5 | N/A | N/A |
| Ma *et al*[106], 2015 | China | 816 | Wantai | 172 | 21.1% | 4 | 0.5% | 0 | N/A | N/A |
| Ren *et al*[107], 2014 | China | 10741 | Wantai | 2945 | 27.42% | 109 | 1.01% | 0 | N/A | N/A |
| Zhuang *et al*[108], 2014 | China | 486 | ELISA based on antigen protein pB166 and MPII | 113 | 23.3% | N/A | N/A | N/A | N/A | N/A |
| Tsoi *et al*[71], 2019 | Hong Kong | 2000 | Wantai | 315 | 15.8% (14.2%-17.4%) | 16 | 0.8% | 0 | N/A | N/A |
| Tripathy *et al*[109], 2019 | India | 2447 | Wantai | 433 | 17.70% (16.23%-19.26%) | 5 | 0.20% | 2 | Ranged from 3.5 × 104 to 4.6 × 105 copies/mL | 1 |
| Katiyar *et al*[72], 2018 | India | 633 | Wantai | 383 | 60.5% | N/A | N/A | 0 | N/A | N/A |
| Gajjar *et al*[110], 2014 | India | 460 | DiaPro | N/A | N/A | 22 | 4.78%  | N/A | N/A | N/A |
| Parsa *et al*[111], 2016 | Iran | 700 | DiaPro | 42 | 6.0% | 5 | 0.71% | 5 (only 50 seropositive blood donors were tested) | N/A | 1 |
| Hesamizadeh *et al*[112], 2016 | Iran | 559 | DiaPro | 45 | 8.05% | N/A | N/A | N/A | N/A | N/A |
| Naeimi *et al*[113], 2015 | Iran | 628 | HEV IgG, Pasto, Iran | 105 | 16.72% | N/A | N/A | N/A | N/A | N/A |
| Ehteram *et al*[114], 2013 | Iran | 530 | DiaPro | 76 | 14.3% | N/A | N/A | N/A | N/A | N/A |
| Taremi *et al*[115], 2007 | Iran | 399 | DiaPro | 31 | 7.8% | N/A | N/A | N/A | N/A | N/A |
| Takeda *et al*[116], 2010 | Japan | 12600 | in-house ELISA | 431 | 3.42% | N/A | N/A | N/A | N/A | N/A |
| Shrestha *et al*[117], 2016 | Nepal | 1845 | Wantai | 773 | 41.9% (39.7%-44.2%) | 55 | 3.0% (2.2%-3.8%) | N/A | N/A | N/A |
| Nasrallah *et al*[118], 2017 | Qatar | 5854 | Wantai | 1198 | 20.46% | 34 | 0.58% | 4 | N/A | N/A |
| Jupattanasin *et al*[119], 2019 | Thailand | 630 | EUROIMMUN test kit | 187 | 29.7% (26.2%-33.4%) | N/A | N/A | N/A | N/A | N/A |
| Africa |
| Traoré *et al*[120], 2016 | Burkina Faso | 1497 | DiaPro and Wantai | 584 | 39% | 13 | 0.87% | N/A | N/A | N/A |
| Ibrahim *et al*[121], 2011 | Egypt | 760 | N/A | N/A | N/A | 3 | 0.39% | 2 | N/A | N/A |
| Meldal *et al*[122], 2013 | Ghana | 239 | 4 commercial assays were used, findings reactive in; at least two serological assays are shown | 11 | 4.6% | 14 | 5.9% | 0 | N/A | N/A |
| Lopes *et al*[123], 2017 | South Africa | 300 | Fortress Diagnostics | 76 | 25.3% | 0 | N/A | N/A | N/A | N/A |
| Ben-Ayed *et al*[124], 2015 | Tunisia | 426 | Globe; Diagnostics Srl ELISA | 19 | 4.46% | N/A | N/A | N/A | N/A | N/A |
| Others |
| Hewitt *et al*[77], 2018 | New Zealand | 1013 | Wantai | 98 | 9.7% (7.9%-11.7%) | N/A | N/A | N/A | N/A | N/A |
| MP Biomedicals | 82 | 8.1% (6.5%-10.0%) |

ALT: Alanine aminotransferase; CI: Confidence interval; DSI: Diagnostic Systems Incorporated; ELISA: Enzyme-linked immunosorbent assay; HEV: Hepatitis E virus; NIH: National Institutes of Health.

**Table 4 Reported cases of transfusion transmitted hepatitis E**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Number of patients** | **Comorbidity** | **Blood component received (*n*)** | **Viral load of transfused blood product IU/mL** | **Genotype** | **Treatment** | **Outcome** |
| Okano *et al*[137], 2020  | 1 | AML on chemotherapy | Plt | N/A | 3b | Nil | Spontaneous resolution and developed HEV antibodies after cessation of chemotherapy for AML |
| Gallian *et al*[138], 2019  | 23 | Solid organ transplant, *n* = 9; allogeneic hematopoietic stem cells transplant, *n* = 4; hematologic malignancies, *n* = 5; immunosuppressant, *n* = 2; immunocompetent, *n* = 3 | RBC *n* = 7; apheresis Plt *n* = 3; whole blood-derived pooled Plt *n* = 6; FFP *n* = 7 | Ranged from 1.14 × 103 to 31 × 62.106 | 3a, *n* = 1; 3c, *n* = 4; 3f, *n* = 16; 3, *n* = 1; 4d, *n* = 1 | Ribavirin, *n* = 15 | Acute HEV infection, *n* = 8; spontaneous resolution, *n* = 4; ribavirin treatment, *n* = 3; immunosuppressant reduction, *n* = 1; chronic HEV infection, *n* = 14, all immunosuppressed; resolution with ribavirin, *n* = 10; resolution with immunosuppressant reduction, *n* = 4; One solid organ transplant recipient did not clear HEV infection despite ribavirin and died of multiorgan failure |
| Ledesma *et al*[139], 2019 | 2 | Allogeneic BMT, *n* = 1; liver transplant, *n* = 1 | Plt | 3 × 104 | 3e | Ribavirin, *n* = 1 | The patient received BMT remained HEV-infected and IgM/IgG-negative until death; the patient with liver transplant was treated successfully with a course of ribavirin |
| Satake *et al*[140]a, 2017 | 19 | Hematologic malignancies, *n* = 6; organ transplant, *n* = 2; systemic disease, *n* = 8; no major comorbidity, *n* = 3 | RBC *n* = 10; Plt *n* = 6; FFP *n* = 3 | Ranged from 1.5 × 102 to 5.3 × 106  | 4, *n* = 2 | N/A | Two patients with malignant lymphoma and two who had received liver transplant developed chronic hepatitis E; the two liver transplant recipients were successfully cleared of HEV by ribavirin |
| Lhomme *et al*[141], 2017 | 3 | Solid organ transplant | One patient received RBC; one patient received RBC and Plt; one patient received Plt and FFP | Ranged from 3.6 to 8.2 log IU | 3, *n* = 1; 3f, *n* = 2 | N/A | N/A |
| Yamazaki *et al*[142], 2017 | 2 | Hematologic malignancies treated with chemotherapy | N/A | N/A | 3b | N/A | Did not become chronic hepatitis E |
| Belliere *et al*[143], 2017 | 1 | Heart transplant | RBC | 1430 copies/mL | 3 | Ribavirin | Died from multi-organ failure despite treatment |
| Riveiro-Barciela *et al*[144], 2017 | 1 | Immunocompetent, admitted for disseminated infection | RBC | 75000 | 3 | Nil | Spontaneous resolution |
| Hoad *et al*[145], 2017 | 1 | Liver transplant | FFP | 947 | 3 | Ribavirin | Resolved with treatment |
| Matsui *et al*[146], 2015 | 1 | AMI post CABG with hemorrhagic cardiac tamponade | Plt | 106.8 copies | 3 | Nil | Spontaneous resolution |
| Huzly *et al*[147], 2013 | 1 | Immunocompromised | Apheresis Plt | 30888-37273 | 3f | N/A | N/A |
| Coilly *et al*[148], 2013 | 1 | Liver transplant | RBC | 3.5 log10 | 3c | Ribavirin | Resolved with treatment |
| Boxall *et al*[149], 2006 | 1 | Lymphoma on chemotherapy | RBC | N/A | 3 | Nil | Spontaneous resolution |
| Mitsui *et al*[150], 2004 | 1 | Hemodialysis | RBC | N/A | 3 | Nil | Subclinical infection without elevated ALT |

aTwo cases were not confirmed by sequence identity and should only be considered as probable TT-HEV.

ALT: Alanine aminotransferase; AMI: Acute myocardial infarction; AML: Acute myeloid leukemia; BMT: Bone marrow transplant; CABG: Coronary artery bypass graft; FFP: Fresh-frozen plasma; HEV: Hepatitis E virus; Ig: Immunoglobulin; Plt: Platelet concentrates; RBC: Red blood cell.